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 Musculoskeletal disease is one of the leading causes of long term physical 
disability and affects hundreds of millions of people worldwide. One of the key 
challenges in bone healing and regeneration is the engineering of an implant that 
incorporates osseointegration to meet the metabolic demands of recovery. Although 
implants are typically expected to last ten years or more, longevity is still not assured and 
the lack of integration into the bone for long-term survival often occurs and leads to 
implant failure. 
 Revision surgery to address such failure involves increased risks, complications 
and costs. The main reason for the failure of these implants is due to aseptic loosening 
which accounts for 60 to 70% of the cases for revision surgery. The success of implants 
is dependent on firm bonding or fixation of implant biomaterial to bone, for optimal 
function and lastingness. Thus the aim of this thesis is to develop orthopaedic implant 
materials with enhanced bioactivity and improved implant-host interactions so as to 
reduce biological related implant failure.  
 In this thesis, various approaches of surface functionalization to confer implant 
materials with bioactivity were developed depending on the materials of interest. At the 
same time, other important material properties such as surface profile, topography, 
stability, cytotoxicity and effects on cellular functions were investigated after the 
functionalization process. The interactions between the fabricated materials and 
biological systems were evaluated with typical cells involved in osseointegration 
including human mesenchymal stem cells, osteoblasts and endothelial cells. Taken 
together it is hoped that the work in this thesis will bring continued breakthroughs in 
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implant technology research which will lead to translational clinical applications for 
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Chapter 1   
Nature and Scope of Thesis 
 Orthopaedic implants form a diverse group of applications and designs. This is 
further compounded by the range of biomaterials available with attendant issues affecting 
success and survivorship. The successful application of an orthopaedic implant depends 
on the complex interplay of a number of factors. Technology and research in this area 
thus need to consider all these complex factors in coming up with improved function and 
outcomes for the future. Within the ambit of this thesis however, we shall be mainly 
focusing on the implant itself.  
 The theme of this project is to promote interaction between biological systems 
and implant materials by using novel applications of functionalization of material 
surfaces with bioactive factors so as to confer materials with bioactivities that can 
potentially enhance their results and longevity. The choice of  materials selected in this 
project include metallic alloys and bioactive factors that can improve bone-implant 
anchorage and osseointegration. The specific aims of the study are: 
1) To develop stable and non-cytotoxic strategies to enhance the bioactivity and 
biointegration of the implant materials. 
2) To evaluate the modified implant materials in terms of the stability of the 
functionalized groups and for cytotoxicity. 
3) To assess biological effects of the functionalized implant material. 
 In Chapter 2, a general overview of the musculoskeletal burden and the different 
categories of orthopaedic implants and the reasons for implant failure will be discussed. 
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Joint replacement implants are among the most important orthopaedic devices in use 
today and accounts for more than half of the orthopaedic implant market [1, 2], therefore  
current development and evolution in one of the most popular and extensively used joint 
implant, 'The total hip arthroplasty implant' will be reviewed [3, 4]. In addition tissue-
implant response, current strategies and research in enhancing orthopaedic implants will 
be examined.  
 In chapter 3, surface immobilization strategies were developed and assessed for 
the functionalization of Titanium substrates with vascular endothelial growth factor 
(VEGF). The binding properties, efficiency, release profile and cytotoxicity of each of 
the various techniques of surface functionalization namely A) physical adsorption, B) 
cross-linking and C) covalent binding with VEGF were analyzed. From the investigation 
a viable technique was chosen which would provide us with the most efficient, facile and 
cost effective method of attaching bioactive molecules to implant materials without the 
risk of cytotoxicity and undesirable effects. 
 In chapter 4, we further characterized the effects of Titanium substrates 
functionalized with VEGF via the chosen technique in terms of surface composition, 
topography and bioactivity. X-ray photoelectron spectroscopy (XPS) was used to track 
the surface composition at each stage of surface functionalization.  Surface topography 
was checked with atomic force microscopy (AFM). Cellular functions  in terms of 
cellular adhesion and proliferation were assessed with human dermal microvascular 
endothelial cells (HDMECs). Biological activity of the immobilized VEGF was evaluated 
with in vitro angiogenesis assay using matrigel and immunofluorescent staining with von 
Willebrand Factor (vWF) and PECAM1 (CD31). The results of the study indicate new 
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possibilities for the use of such functionalized surfaces for implanted medical devices. 
The coating of a biomimetic polymer film onto Titanium substrate followed by VEGF 
conjugation provides a means for applications where revascularization around implants 
would be beneficial. This may serve as a model for the immobilization of other bioactive 
factors onto various different types of metallic substrates. 
 In chapter 5, using the methodology developed in chapter 4, we investigated if 
this technique is viable in another metallic alloy with a different bioactive factor. In this 
instance Cobalt Chromium and bone morphogenetic protein 2 (BMP2) was evaluated. 
The binding properties, efficiency, release profile and cytotoxicity were analyzed. XPS 
was used to verify the successful grafting procedures at various stages of surface 
functionalization. Cellular functions with osteoblastic cells were assessed measuring 
alkaline phosphatase (ALP) activity and calcium mineral deposition. The results from this 
study showed that the immobilization of BMP2 on Cobalt Chromium has the ability to 
confer enhancement of cell-implant interactions, promoted bone matrix formation and 
bone growth. Thus the immobilization of BMP2 on Cobalt Chromium implants may be 
beneficial in the establishment of a direct interface between the bone and the implant 
without intervening fibrous tissue layer which may provide a promising means for 
enhanced osteogenesis. 
 In chapter 6, we sourced for an alternative molecule as a viable replacement for 
BMP2. BMP2 has the shortcomings of needing a huge quantity and a high immobilized 
density to elicit a response. It is also expensive and has a short shelf life. Hence a 
synthetic peptide CKIPKASSVPTELSAISTLYL with a cysteine amino acid at the N-
terminus was produced. A comparison of the binding efficiency and dosage response of 
 15 
the peptide versus BMP2 was evaluated. Surface topography was evaluated from the 
surface profile determined by AFM. Cellular functions, morphology, viability, ALP assay, 
alizarin red staining and BMP signaling via smad-dependent pathways were assessed. 
The study showed that the usage of the synthetic peptide in implant functionalization is a 
cheaper and viable alternative compared to BMP2, especially in instances where costs 
may be prohibitive.  
 Chapter 7 gives the overall conclusion of the current work done and Chapter 8 


















Introduction    
2.1  The Musculoskeletal Burden 
 Musculoskeletal disorder is a major public health concern and accounts for 33% 
of all cases of disability [5]. Orthopaedic research especially in the fields of biomedical 
engineering is an important tool for treatment. However long term outcome is not 
guaranteed and 10% of patients would need to undergo revision surgery at 10 to 15 years 
and the instances increases to 30% for heavier and younger patients [6]. Revision surgery 
is a complex procedure, costly to perform and leads to prolonged hospitalization with 
high health and social costs. In addition the outcome may not be as good as the first 
replacement due to extensive surgery required for the procedure and higher patient 
morbidities (longer surgery, more blood loss, etc.). The most common cause for revision 
surgery is due to aseptic loosening where the bone fail to grow into the surface of the 
implant [7]. Biological failures continue to prevent true longevity of orthopaedic implants, 
hence innovation is needed to reduce the necessity for revision surgery surrounding this 
common orthopaedic procedure. 
 The orthopaedic implant sector forms a significant portion of the worldwide 
biomedical industry. In the US alone, the orthopaedic implant market was estimated at 
over US$14 billion in 2008, and this is projected to rise to US$23 billion by the year 
2012 [8]. Within this large and diverse field of orthopaedic surgical practice, there are 
four major implant applications: reconstructive joint replacements, spinal implants, 
orthobiologics and trauma implants. Of these joint replacement implants are among the 
most important orthopaedic devices in use today and accounts for more than 50% of the 
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orthopaedic implant market [1, 2]. The clinical need is anticipated to continue to grow for 
the foreseeable future, boosted by local and worldwide ageing populations, as well as 
increasing prevalence of physically active lifestyles and higher expectations of quality of 
life in older age groups. 
 
2.2  Orthopaedic Implants 
Orthopaedic implants are medical devices used for the treatment of musculoskeletal 
diseases. They are used for fixation of bones and to replace damaged joints. Generally 
they are available for the elbow, shoulder, hip and knee. Orthopaedic implants may 
consist of a single type of biomaterial or comprise a number of different biomaterials 
working together in modular parts, such as in a total hip replacement system which may 
contain up to three or more different materials such as polymethylmethacrylate (PMMA 
or bone cement), Cobalt Chromium and Titanium alloy. Prime examples of widely-used 
orthopaedic implants would include prosthetic hip and knee replacements for various 
types of arthritis affecting these joints, spinal fusion instruments for stabilizing 
degenerate and unstable vertebral segments, and fracture fixation devices of various types 
such as plates, screws and intramedullary rods. Less common implants in which the 
technology may still be in varying phases of maturity, as well as those which are in 
development but may not yet be established in clinical usage, would include other joint 
replacements such as for shoulder, ankle, elbow and small joints, artificial vertebral disc 
replacements, and orthobiological implants such as artificial scaffolds for osteochondral 
defects and knee meniscal implants. 
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 Despite the large number of orthopaedic medical devices in use today, they are 
predominantly make up of only a few metals and polymers. Metallic alloys such as 
Cobalt Chromium and Titanium continue to be one of the most important components 
used in orthopaedic implant devices. They have favorable properties of high corrosion 
resistance, strength, rigidity and fracture toughness. Cobalt Chromium alloys are used in 
bearing surfaces due to their hardy surfaces that resists abrasive wear and very high 
corrosion resistance [2]. However Cobalt Chromium alloy is known to have much less 
potential for osseointegration. Titanium alloys are used in non-weight-bearing surface 
components such as femoral necks and stems as they have lower modulus of elasticity, 
resulting in less stress shielding of bone [9]. The presence of a naturally formed oxide 
layer on the Titanium surface also increases its biocompatibility and bioactivity [10]. 
Nonetheless the osseointegrative bioactivity is still often not sufficient to attain true 
adhesion between the implant and bone, which may ultimately lead to mechanical 
instability and implant failure [11].  
  
Reasons implant may fail 
 Orthopaedic implants developed by various manufacturers have different designs. 
Each manufacturer have their own differing theories on implant designs for specific 
orthopaedic applications. Generally there are certain guiding principles that will affect the 
ultimate viability of an implant. The design of the implant has to take into account 
biomechanical and biological factors that may affect its success. Conformity to native 
anatomy, material properties and mechanical strength appropriate for the targeted 
function and environment are some of the considerations that come into play. 
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 Despite the benefits and successes of these medical devices, their use are not 
without risk of adverse effects. Success in the application of an orthopaedic implant 
would depend on various factors and implants may fail due to physiologic reasons such 
as infection, loosening, dislocation and patient-related factors.  
Infection 
 The presence of a large foreign object in the body can serve as a surface for the 
bacteria to latch onto. Infection is caused by the susceptibility of the implant material to 
infection by inoculated or circulating bacteria, which can be impossible to eradicate 
without implant removal. The tissue that has been operated on has an altered blood 
supply which may be inadequate to combat infection. More importantly a chronic fight 
against infection would endanger the life of the patient. However with current antibiotic 
regimens and surgical techniques, the risk of infection is moderately low [12].  
Loosening 
 When implants were placed in they were intended to stay fixed for a long time 
and bone was expected to grow into the surface of the implant. Unfortunately this does 
not always happen and leads to micromotion and the generation of wear particles on the 
surfaces of the implant [13]. Eventually this causes aseptic loosening as the bonds of the 
implant to the bone are destroyed by the body's attempts to digest the wear particles. 






 Dislocation occurs when an implant become misaligned or is displaced from its 
normal position. The rate of dislocation is roughly about 10% [14] and may be caused by 
inadequate soft tissues, incompatibility issues, bony or scar tissue impingement and 
loosening. 
Patient-related factors  
 Heavier and obese patients have a higher chance of wear and loosening. Young 
and active patients have a higher incidence of revision [6]. Patients with medical history 
such as having a previous hip fracture, arthritis and avascular necrosis are also at a higher 


























2.3  Joint Replacement Implants 
 
 The total hip arthroplasty which is one of the main joint implants in use has been 
named the operation of the century [3]. Total hip arthroplasty implants typically consist 
of a stem, femoral head and an acetabular cup, and are used to replace damaged natural 
bearing surfaces in patients. 
 
Figure 2.1 Diagram of a typical hip implant. Acetabular cup and femoral head is usually 
made of Cobalt Chromium for the bearing strength, while the femoral stem is usually 
composed of Titanium for the biocompatibility.  
 
Developments and evolution in hip implants 
 Throughout their evolution, total hip arthroplasty implants have incorporated 
metal-on-metal, ceramic-on-ceramic and metal-on polyethylene designs, each with its 
own distinct advantages and unique drawbacks. New combinations and improvements in 
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materials are being developed, however at present there is still no clear winner in the 
search for the perfect bearing surface material combination. 
 
Metal-on-polyethylene  implants 
 From the early to mid 20th century, various different combinations of materials 
were being explored as candidate bearing surfaces for total hip arthroplasty. High-density 
polyethylene was first used clinically by Sir John Charnley and this bearing material 
dominated the total hip replacement implants in the 1970s. First-generation results of 
metal-on-polyethylene hip arthroplasty showed impressive long-term results of 77% to 
81% survivorship at 25 year follow up [15, 16]. However a new complication was arising, 
presenting as insidious hip pain and appearing on radiographs as massive bone lysis 
resembling metastatic malignancy [17]. An outbreak of periprosthetic loosening took the 
orthopaedic world by surprise. Tissue examinations revealed an inflammatory response 
around the implant interface with macrophages displaying minute particles embedded in 
them [18]. In the beginning these particles were thought to be bone cement, leading to the 
erroneous term “bone cement disease” being coined in 1987. Eventually it was 
ascertained that the problem was due to polyethylene wear particles stimulating a 
macrophage response, but not before the perceived problem with bone cement had given 
impetus to a new direction of development in hip arthroplasty: that of uncemented hip 
designs relying on biological fixation. The identification of polyethylene wear particles as 
the main cause in periprosthetic osteolysis in turn led to a resurgence in interest in 
alternate bearing combinations. Another impending issue is that younger, active patients 
as opposed to their older and more sedentary counterparts inflict as much as 40 fold 
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greater wear on their hip joint bearing surfaces [19]. Therefore alternative bearing 
surfaces such as ceramic-on-ceramic or metal-on-metal (i.e. hard on hard) as compared to 
metal on polyethylene (hard on soft) are being developed to address these issues.   
 
Ceramic-on-ceramic implants 
 In 1970s, the first ceramic-on-ceramic total hip replacement was introduced by 
Pierre Boutin [19]. However during then there were problems as the material quality was 
not as good as it is today and strengths were much lower. Recent improvements over the 
years have now created ceramic powders with inherently higher strength. The ceramic-
on-ceramic hip replacement implants are made from aluminum oxide ceramic. Ceramic 
components are extremely wear resistant and have much smaller debris particles 
compared to that of  metal-on-polyethylene and metal-on-metal bearing surfaces. Ultra-
smooth surfaces, hardness and very low wear rates have popularized ceramic as a choice 
for younger patients so as to delay or prevent the need for revision surgery. However the 
use of ceramics too, have risks. They are more fragile than metals or polymers and as 




 Metal-on-metal total hip replacements were first used in the 1930s, and further 
developed by pioneering surgeons like McKee and Ring in the 1950s and 1960s [20]. The 
early generations suffered from inferior material quality, poor fixation and generally had 
high device failure rates. As a result the better performing metal-on-polyethylene 
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prostheses supplanted metal-on-metal designs as the preferred bearing surface for several 
decades. In the past decade, improved industrial fabrication and manufacturing processes 
have incorporated stronger, more wear resistant metallic alloys such as Cobalt Chromium 
and Titanium into hip implant designs which have spurred a renewed interest in the 
metal-on-metal hip prostheses. Use of metal-on-metal hip implants has been further 
bolstered by their more-recent success in hip resurfacing applications. Hip resurfacing 
was developed as an alternative to total hip replacement. Hip resurfacing entails 
reshaping the patient’s natural femoral head and then capping it with a matching metal 
cup rather than replacing the entire joint. Long-term follow-up of implants using metal-
on-metal bearings showed good survival and wear resistance without the problems 
associated with polyethylene bearing surfaces [21]. Polyethylene bearing surfaces have 
high wear rates in the region of 0.1 mm per year compared in contrast to 0.004mm per 
year for metal surfaces. Unlike ceramics, metal is also ductile, not brittle, hence, implant 
sizes can be kept thinner without risk of implant fracture. Thus, for a given acetabular 
shell size, a large head diameter can be used, which provides enhanced joint stability and 
a large range of movement before the neck impinges on the socket. Another advantage of 
metal-on-metal bearings is that they are also self-polishing, allowing for self-healing of 







2.4  Tissue-Implant Response 
 
 All implant materials will elicit some response to the host and none are truly 
considered inert [22]. The response generally occur at the bone-implant interface and is 
dependent on various factors. The most important factors in implant studies would 
include the surface topography, intrinsic properties of the implant and any implant-
mediated biological reactions [23]. 
 Generally there are 2 types of implant-tissue responses [24-26]. The first type is 
the response of the hosts' tissues to the toxicity of the implanted material. Implanted 
material may be toxic or releases chemicals that damage the surrounding tissues. The 
second response which is also the commonest is the formation of a nonadherent fibrous 
capsule between the implant and the hosts' tissues. This is a natural response to protect 
the body from a foreign object which may eventually lead to complete fibrous 
encapsulation [27]. Metallic alloys and polymers when implanted into bone may be 
surrounded by both bone and fibrous tissue. Under ideal conditions osseointegration 
would be desired, however the instances of the development of a fibrous capsule is high 















2.5  Current Research in Enhancing Orthopaedic Implants 
  
 Two types of fixation are usually used to hold the implants in place. Cemented 
fixation would use PMMA to anchor the implant in place while cementless fixation 
(direct biological fixation) would rely on bone growing into the surface of the implant 
achieving solid fixation. Patients will not be able to feel the difference between the two 
types of fixation, and the fixation technique chosen would be based on the bone stock 
quality, age and the demands of the patient. Controversy still exists regarding the optimal 
method of fixation, although traditionally the method of fixation of an implant to bone 
has relied on the use of bone cement. However due to the problems of implant loosening 
and loss of bone stock observed especially in younger and more active patients there is a 
shift from cemented fixation to direct biological fixation. The idea of implanting 
prostheses without bone cement and eventually becoming a part of the body with 
complete incorporation is becoming more popular. Nonetheless the comparative 
outcomes, advantages, disadvantages and preferred indications of cemented versus direct 
biological fixation remain unresolved. The superiority of either fixation technique is still 
not established. 
Bone-implant interface 
 So far most research efforts have been concentrated on improving the bone-
implant interface, with the aim of enhancing bone healing and implant integration via 
either physical or chemical approaches [28]. The physical approach is focused on the 
modification of the implant surface morphology and topography using mechanical 
methods such as machining, acid-etching, plasma spraying, grit-blasting and anodization 
 27 
to improve the microtopography of the surface. The rationale behind this is that an 
increase in surface roughness of the implant material would provide a higher level of 
surface energy which would improve bone anchorage, matrix protein adsorption, 
osteoblasts functions and ultimately osseointegration [29]. 
 The chemical approach is towards the creation of a bioactive implant surface via 
application of coatings onto the implant layer by biochemical and physicochemical 
techniques. In biochemical techniques, organic molecules such as growth factors, 
peptides or enzymes are incorporated to the implant layer to affect specific cellular 
responses [30]. While in physicochemical techniques, the incorporation is achieved with 
inorganic phases such as calcium phosphate which may increase the biochemical 
interlocking between bone matrix proteins and surface materials thereby enhancing bone-
bonding [29]. Many implant modifications may combine both physical and chemical 
engineering methods, in the following sections we will discuss some of the more popular 
strategies used to enhance implant integration and bone-bonding. 
Inorganic coatings 
 Calcium phosphate coating has been widely used in the orthopaedic field due to 
their similarity with the mineral phase of bone [31] and are known for their bioactive 
properties which are beneficial in bone-bonding [32]. As calcium phosphate generally 
lack the mechanical strength for use as bulk materials under loaded conditions, they are 
often coated onto the surface of metallic implants. There are several studies published 
which have shown the favorable use of calcium phosphate coatings in increasing bone-
implant interface, implant anchorage and integration [33]. The calcium phosphate layer 
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functions as a physiological transition between the implant surface and the hosts' tissues 
which guides bone formation along the implant surface and the surrounding tissues. One 
of the most successful method for the application of calcium phosphate coatings is via the 
plasma-spraying method due to its advantage of extensive coating capability and high 
deposition rate. However despite numerous findings [34] that report the beneficial 
osteoinductive properties of plasma-sprayed calcium phosphate coatings, there are still 
some concerns regarding its use. Plasma-sprayed coatings are not uniform and there is 
poor control over thickness and surface topography, which may result in implant 
inflammation when particles are released from these heterogeneous coatings. To 
overcome these drawbacks, various other deposition strategies have been developed and 
employed such as biomimetic deposition, electrophoretic deposition and electrospray 
deposition etc. However care should be taken when comparing the efficacy of each of 
these methods which would require a comprehensive evaluation of both biological 
response and clinical performance. Although calcium phosphate coatings have been 
shown to be beneficial in enhancing bone-bonding, there is still no general consensus on 
the use of calcium phosphate coating systems. The main problems include large variation 
in the quality of calcium phosphate coatings, even between different batches and market 
forces which offer other cheaper alternatives [35]. 
Organic coatings 
 Surface modification of implant materials with growth factors and peptides is 
gaining popularity in the recent years [36, 37]. Various therapeutic biomolecules of 
interest can be immobilized onto implant surfaces to enhance the bone-implant interface 
interactions. Currently more popular approaches would include the immobilization of 
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bone growth factors such as bone morphogenetic proteins (BMPs) to enhance 
osteogenesis and the deposition of peptide sequences to induce specific cellular functions. 
Growth factors immobilized on orthopaedic devices have been reported to enhance 
osteoblastic activity and favor implant integration [38]. The most commonly used growth 
factors in orthopaedics are members of the transforming growth factor beta (TGF-β) 
superfamily including the BMP family, especially BMP2 and BMP7. Growth factors may 
be physically adsorbed or covalently grafted onto the implant surface and various studies 
have shown that the loading of implant with these factors can enhance interactions at the 
bone-implant interface and aid the remodeling process ultimately improving implant 
integration [39-41]. However critical factors in the successful use of growth factors in 
orthopaedic devices are the optimum dosage, exposure period and release kinetics, all 
have to be considered carefully to avoid the detrimental effects associated with growth 
factor use such as high initial burst rate, ectopic bone formation and short half-life. More 
recently, peptide sequences with the ability to target specific osteogenic cellular functions 
of differentiation and mineralization have been developed [42, 43]. These short 
functional fragment derived from the original protein have increased shelf life, can be 
synthetically produced and are more resistant to denaturizing effects. Their usage would 
provide significant clinical benefits over the use of conventional proteins. They can be 
linked to the implant surface to provide biological cues for bone formation. Additionally 
other peptide sequences in use include the RGD, YIGSR, IKVAV and KRSR which have 





Organic–inorganic composite coatings 
 
 Research in the recent years have concentrated on the development of bioactive 
composite coatings which mimics the structure of the bone tissue. These composite 
coatings would combine calcium phosphate with growth factors, peptides, antibodies etc. 
to enhance interactions at the bone-implant interface. However due to the fact that often 
high temperatures or non-physiological conditions are needed in the preparation of 
calcium phosphate coatings, only physical adsorption is employed in deposition of the 
biomolecules on the implant surface [47, 48]. However with physical adsorption 
techniques, initial high burst rate is often observed, which is not desired [49]. Therefore 
coating techniques that create a gentle sustained release kinetics are preferred. A recently 
published paper have shown that calcium phosphate coating combining slow release of 
antibiotics, aids in early success at recruitment of bone cells [50]. Many other studies 
have shown that depositing BMP2 and TGF-β onto the implant surface would greatly 
enhance bone-bonding at the bone-implant interface [38, 47]. The biological efficacy of 
orthopaedic implants can be improved greatly by both physical and chemical 
modifications. The use of a wide multitude of engineering techniques in the  
manipulation of surface topography, morphology and incorporating the use of various 
inorganic and organic components would directly influence the response in the local 
bone-implant interface and the apposition of new bone. With the development of new 
techniques and strategies on composite coatings to better mimic the human bone structure 
this would result in a new generation of orthopaedic implants with improved implant 




 Despite the successes of orthopaedic implants, their usage are not without risks 
and the most common cause of implant failure is due to aseptic loosening. Aseptic 
loosening alone causes about 60 to 70% of the cases for revision surgery and the reason is 
due to sub-optimal osseointegration [51, 52]. Strategies to enhance osseointegration 
include the use of surface modification techniques to enhance implant integration with 
bone and to induce acceleration of the bone healing phenomena. Many attempts to 
activate the surface have been made based on the control of surface topography, surface 
energy and biological cues [53]. Therefore to increase the success of implant integration 
and to reduce revision surgery, our study will investigate surface modification of metallic 
implant materials with biomimetic coatings immobilized with therapeutic biomolecules 
of interest to enhance bone-implant interface interactions. The specific metallic implant 
materials and bioactive factors investigated are as follows: 1) Metallic alloys (Titanium 
and Cobalt Chromium) which will provide the structural support for mechanical function, 
and delivery of growth factors. 2) Bioactive factors (VEGF, BMP2 and BMP Peptide) 









Chapter 3  
 
3.1  Novel Strategies for Conferring Bioactivity to Implant Material  
 Despite the advances in current implant technology, there are still problems 
associated with their usage including loosening and tissue rejection. A variety of implant 
materials have been developed for orthopaedic applications however the results have not 
been fully satisfactory. The clinical strategies to manage musculoskeletal defects would 
center around three components: cells, structure and growth factors. For the design of 
implant materials, cells and proteins at the implant interface plays a critical role [54]. The 
utilization of biosignal proteins such as growth factors for development of bioactive 
implant materials holds great potential. Especially due to the scarcity of stem cells in the 
body, materials which regulates cellular functions such as adhesion, growth and 
differentiation are desired. 
 One promising way to incorporate growth factors usage with implant materials 
would be by surface immobilization of growth factors. Soluble growth factors work by 
binding with cognate receptors on cells to form complexes which would result in 
autophosphorylation of the cytoplasmic domains of the receptors and this 
phosphorylation activates intracellular signal transduction. The formed complexes are 
then aggregated and internalized into the cells by both clathrin-dependent and clathrin-
independent mechanisms which leads to the recycling of the receptors for degradatory 
down-regulation [55]. Similarly immobilized growth factors work by forming complexes 
with the cell surface receptors, however the signal transduction is expected to last longer 
than soluble growth factors due to the inhibition of the internalization process.  
Multivalency is another important phenomenon responsible for this prolonged enhanced 
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mitogenic effect. Multivalent ligands interact and bind avidly to multiple surface cell 
receptors through several binding modes. This enhances the formation of ligand-receptor 
complexes which are critical for signal transduction and the multivalent ligands are able 
to stabilize and prevent lateral diffusion of the formed complexes leading to the 
prolonged effect. Figure 3.1 shows the interactions of cells with the different forms of 
growth factor and the cross relationship between dosage and mitogenic effects. 
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Figure 3.1 Effects of soluble growth factors compared to immobilized growth factors 
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 In order to effectively derive the effect from immobilized growth factors, 
strategies have to be developed that can optimize the structure to elicit the desired 
biological response. One of the problems encountered with implant materials for surface 
functionalizaton is the lack of suitable chemical groups on the surface. For more 
versatility and applicability, the concentrations of the OH group and other reactive groups 
such as amino or carboxyl groups have to be increased. The initial organic layer 
immobilized on the implant materials can then be used as a tether for biomolecular 
components used to mediate cell attachment. Another issue which merits investigation is 
the control of the retention and/or release of the biomolecules from the implant surface. 
The easiest and most common method employed for delivery of biomolecules is physical 
adsorption, which unfortunately provides little control over the delivery and orientation 
of the biomolecules. Bonding of the biomolecules and use of coatings incorporating them 
would be alternative methods of delivery to the bone-implant interface. Regardless, the 
preferred and chosen immobilization technique would depend on the specific working 
mechanism of the biomolecules. Given the above scenario, chemical modification 
(functionalization) of biomaterials in order to enhance biocompatibility and promote 
osseointegration has great potential in addressing the problems of prosthetic joint implant 
longevity and survival.   
 
Immobilization techniques  
 Immobilization techniques are broadly classified into four categories, namely a) 
physical adsorption (via van der Waals or electrostatic interactions), b) physical 
entrapment (use of barrier systems), c) cross-linking and d) covalent binding. The choice 
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of the technique would depend on the nature of the bioactive factors, substrates and its 
application. It will not be possible to have a universal means of immobilization, however 
developing a viable methodology which can provide for a facile, secure immobilization 
with good interactions for orthopaedic implants is vital. 
 
Physical adsorption  
 This is the simplest of all the techniques available and does not alter the activity 
of the bioactive factors. Physical adsorption techniques are mainly based on ionic and 
hydrophobic interactions. If the bioactive factors are immobilized via ionic interactions, 
adsorption and desorption of the factors will depend on the basicity of the ion exchanger. 
A reversible dynamic equilibrium is achieved between the adsorbed factors and 
substrates which is affected by the pH as well as ionic strength of the surrounding 
medium. Hydrophobic interactions offer slightly higher stability with less loss of the 
factors from the surface of the substrates. Although physical adsorption systems are 
simple to perform and do not require extensive treatment to the bioactive factors and 
substrates used however there are certain drawbacks. These systems suffer from low 




 This method is employed with barriers including natural polymers like gelatin, 
agar and alginate entrapment systems. Other synthetic polymers employed include resins, 
polyurethane prepolymers etc. Some of the major limitations of the entrapment system is 
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the diffusional problem where there is possible slow leakage during continuous use due 
to the small molecular size of bioactive factors, and steric hindrance which may affect the 
reactivity of the factors. Recent development of hydrogels and water soluble polymers 




 Bioactive factors can also be immobilized through chemical cross-linking via 
homo- as well as heterobifunctional cross-linking agents. Among these glutaraldehyde 
cross-linking are the most popular due to its low cost, high efficiency and stability [56-




 Covalent binding is another technique used for the immobilization of bioactive 
molecules. The functional groups investigated are usually the carboxyl, amino and 
phenolic group of tyrosine. Bioactive factors are covalently linked through functional 
groups in the factors not essential for the bioactivity. The covalent binding should be 
optimized so as to protect the active site and not alter its conformational flexibility.  
 Therefore based on the above scenario, the objective in this part of the study was 
to devise a suitable methodology to immobilize VEGF onto the surface of Titanium alloy 
substrates (the reason for the choice of the growth factor and substrate will be explained 
in the following chapter). As physical entrapment is not suitable in this case of improving 
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the bone-implant interface via the surface of the implant material, therefore this system is 
not investigated. The binding properties, efficiency and cytotoxicity of each of the 
various functionalization procedures with VEGF were analyzed. We aim to use the above 
scheme as a means to develop an efficient and effective modification strategy to promote 














3.2  Materials and Methods  
Materials 
 Ti-6Al-4V (denoted as Ti in the subsequent discussion) foils were purchased from 
Goodfellow Inc. of Cambridge, UK. Recombinant human VEGF was obtained from 
R&D Systems, US. The viscosity-average molecular weight was approximately 2.2 X 105 
as determined by the viscometric method. The degree of deacetylation was 84% as 
determined by elemental analysis using the Perkin-Elmer Model 2400 elemental analyzer 
[10]. 3,4-dihydroxyphenylalanine (dopamine) and glutaraldehyde were obtained from 
Sigma-Aldrich Chemical Co. Ultrapure water (>18.2 MG cm, Millipore Milli-Q system) 
was used in the experiments. The CellQuanti-MTTTM cell viability assay kit was 
purchased from BioAssay Systems. Endothelial Cell Growth Medium MV Bulletkit CC-
3125 were purchased from Lonza Walkersville, Inc. 
 
Preparation of substrates 
 Ti foils (0.52 mm thick) were cut to a size of 1 cm × 1 cm. The substrates were 
polished using 600 and 1200 grid sandpaper and then sonicated for 10 min in water. The 
carbide deposited during polishing were removed by sonicating the substrates in Kroll’s 
reagent (4.0% HF, 7.2% HNO3, 88.8% water) for 10 min [59]. The reaction was 
terminated by the addition of 1 N sodium hydroxide. The substrates were then cleaned 
ultrasonically for 10 min each in dichloromethane, acetone, water and placed in 40% 
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HNO3 for 40 min for surface passivation. The acid-treated substrates were then rinsed 
thoroughly with water. 
 
Figure 3.2 Substrates preparation to 1 cm by 1 cm and placing them in 24 well plates for 
subsequent experiments. 
Energy-dispersive X-ray spectroscopy (EDX) 
 Unmodified Ti substrates were coated with platinum and the surfaces of the 
substrates were analyzed using a scanning electron microscope equipped with energy-
dispersive X-ray spectroscopy (SEM-EDX) (JEOL, model 5600LV). 
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Cell culture 
 HDMECs (Lonza Walkersville, Inc) were cultured in endothelial cell growth 
medium MV and passage 5 HDMECs were used for the analysis of cell viability assay. 
The cells were incubated at 37 °C in a humidified atmosphere of 5% CO2 with the growth 




 Ti substrates were coated with VEGF in 1 μg/ml concentration dissolved in a 
mixture comprising 0.1% gelatin and 1% low-melting agarose in the ratio 1:1, and 
allowed to dry at room temperature overnight. The substrates were then gently rinsed 
with PBS and allowed to dry. A second thin coating of the gelatin/agarose mixture was 
then layered over each substrate. The substrates were rinsed with PBS and allowed to dry 
before use. The substrates are denoted as Ti-VEGF in the subsequent discussions. 
 
Cross-linking  
 Dopamine was anchored to the surface of the Ti substrates by immersing in a 
1mg/ml aqueous solution of dopamine overnight in the dark. The substrates were then 
thoroughly rinsed with ultrapure water to remove the unattached dopamine and dried 
under nitrogen flow. Subsequently, the substrates were immersed in a stirred 3% aqueous 
solution of glutaraldehyde (pH=8.0) at room temperature overnight. Glutaraldehyde acts 
as a cross-linking agent by providing the reactive aldehyde groups for bonding with 
dopamine and the free amino groups of VEGF [60, 61]. The substrates were rinsed with 
water to remove unbound glutaraldehyde. The glutaraldehyde-treated substrates were 
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then coated with VEGF in 1 μg/ml concentration and allowed to air dry in a sterile 
environment. Following which, the substrates were rinsed 3 times with sterile PBS to 
remove unattached VEGF and left to air dry in a sterile environment before use. The 
substrates are denoted as Ti-GLU-VEGF in the subsequent discussions.  
 
 Figure 3.3 Schematic diagram showing glutaraldehyde cross-linking with proteins. 
Covalent binding 
 Polydopamine was anchored to the surface of the Ti substrates via immersion in a 
2 mg/ml solution of dopamine (10mM Tris buffer, pH=8.5) overnight in the dark. Under 
alkaline conditions, dopamine self-polymerize to form a thin layer on the surface of the 
Titanium substrates via strong intermolecular interactions [62, 63]. The substrates were 
then rinsed with copious ultrapure water to remove the unattached dopamine and dried 
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under nitrogen flow. The polydopamine-grafted Ti substrates were then coated with 
VEGF in 1 μg/ml concentration dissolved in deoxygenated 10mM Tris buffer, pH=8.5 
and incubated overnight in a humid atmosphere at room temperature. Polydopamine 
coating is a very complex surface having its own pH-dependent behaviour and its precise 
chemical composition is still unknown [62, 63]. Two functional groups catechol and 
quinone are present on the polydopamine coating, and under alkaline conditions, latent 
reactivity is shifted towards the quinone groups [62] which is expected to react with the 
amine groups on the VEGF molecule.  The substrates were then washed three times with 
sterile PBS to remove unattached VEGF and left to air dry in a sterile environment before 
use. The substrates are denoted as Ti-PDOP-VEGF in the subsequent discussions. 
 
Figure 3.4 Schematic diagram showing polymerization of dopamine under alkaline pH 






 The chemical composition of the surfaces was analyzed by X-ray photoelectron 
spectroscopy (XPS) on an AXIS HSi spectrometer (Kratos Analytical Ltd, UK) with an 
AlKα X-ray source (1486.6 eV photons). All binding energies (BEs) were referenced to 
the C 1s hydrocarbon peak at 284.6 eV.  
 
Binding efficiency 
 To determine the binding efficiency of the surface functionalization procedures, 
the quantity of VEGF in the loading solution and the combined washing solution was 
performed using an enzyme-linked immunosorbent assay kit (VEGF ELISA, R&D 
System, Minneapolis, MN) according to the manufacturer's instructions. The surface 
density of bound VEGF was calculated from the difference between the initial and 
remaining VEGF in the washing buffer. 
 
Cytotoxicity assay 
 After 1 week of culture, the viability of HDMECs on the Titanium substrates was 
assessed with MTT assay. MTT assay is based on the conversion of yellow MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to purple formazan by 
metabolically active cells. The insoluble purple formazan product is then dissolved in a 
solubilization reagent into a coloured solution. The absorbance of the resulting coloured 
solution was quantified by measuring at a wavelength of 570 nm by a spectrophotometer. 
Briefly, a suitable quantity of MTT reagent was added to the cells at day 7 of culture on 
the different substrates and then incubated for 4 hours at 37 oC. A suitable amount of 
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solubilization solution was added to respective cultures and then gently mixed on an 
orbital shaker for one hour at room temperature. The intensity of the colour in each well 
was measured at 570nm on an absorbance plate reader. 
 
VEGF release overtime 
 To measure the amount of VEGF being released into the culture medium, Ti-
VEGF, Ti-GLU-VEGF and Ti-PDOP-VEGF substrates were subjected to soaking in PBS 
for 30 days at 37 °C and 7 time points were measured.  
 
Statistical analysis 
 At least three samples per time point for each experimental condition were used. 
The data were tested for normal distribution by Shapiro-Wilk test. One-way analysis of 
variance (ANOVA) post-hoc Tukey test was used to assess the normally distributed data 















3.3  Results 
SEM-EDX characterization 
 SEM-EDX was used to characterize the Ti substrates obtained from the 
manufacturer to check for the uniformity and quality of the alloy obtained. From the 
results (Fig. 3.5) more than 90% of the substrates consist of the element Ti and is 




Figure 3.5 Elemental analysis of unmodified Ti substrates from three different  regions. 
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Surface characterization 
 The XPS wide scan spectra of the (A) pristine Ti, (B) Ti-VEGF, (C) Ti-GLU-
VEGF and (D) Ti-PDOP-VEGF and their corresponding surface elemental compositions 
are shown in Fig. 3.5. and Table 3.1. In the wide scan spectrum of the pristine Ti (Fig. 
3.6(A)), the predominant components are C 1s (285 eV), Ti 2p (460 eV) and O 1s (530 
eV). Successful anchoring of dopamine and glutaraldehyde was indicated by a increase in 
the C 1s and N 1s peak intensities and a concomitant decrease in the Ti 2p peak intensity 
(Figure 3.6(C,D)), while successful deposition of the growth factor on the Ti substrate 
was indicated by an increase in the N contents. The changes in the surface atomic ratio of 
the functionalized substrates are quantified and summarized in Table 3.1.  
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Table 3.1 Elemental Composition* at the Surface of Pristine, Ti-VEGF, Ti-GLU-VEGF 
and Ti-PDOP-VEGF substrates as Determined by XPS. 




































Figure 3.6 XPS wide-scan spectra of (A) pristine Ti, (B) Ti-VEGF, (C) Ti-GLU-VEGF 
and (D) Ti-PDOP-VEGF to determine the chemical composition of the surfaces at each 
stage of modification. 
 
Determination of bioconjugation 
 The amount of VEGF bound to the  coated substrates was determined by ELISA 
kit to be 43 ± 5.0 ng/cm2 (86%), 28 ± 2.5 ng/cm2 (56%), and 26 ± 2.5 ng/cm2 (52%) for 
Ti-VEGF, Ti-GLU-VEGF and Ti-PDOP-VEGF substrates respectively. 
 
Cytotoxicity assay 
 Cell viability on the control, pristine Ti, Ti-VEGF, Ti-GLU-VEGF and Ti-PDOP-
VEGF substrates were assessed using the MTT assay, to give an indication of the effect 
of the substrates on the survival and proliferation of the attached cells after 1 week of 
culture (Fig. 3.7)  
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Figure 3.7 Cell viability as measured by MTT assay on the control, pristine Ti, Ti-VEGF, 
Ti-GLU-VEGF and Ti-PDOP-VEGF substrates after 1 week (n=3). The assay showed 
that the Ti-VEGF and Ti-PDOP-VEGF substrates do not affect cell viability while Ti-
GLU-VEGF substrates may be toxic to cells.  
 
VEGF release overtime 
 There is no release of VEGF from the Ti-GLU-VEGF and Ti-PDOP-VEGF 
substrates, while VEGF is progressively released in the Ti-VEGF substrates and its 
concentration in solution reaches a peak at about day 15 (Fig.3.8). 
 
 
Figure 3.8 Concentration of VEGF in PBS, expressed as percentage of the initial coating 
concentration of VEGF on Ti-VEGF, Ti-GLU-VEGF and Ti-PDOP-VEGF substrates 








3.4  Discussion 
 Several methods of immobilizing angiogenic growth factors onto substrates have 
been studied and reported [64-69]. In our study here we investigated the efficacy of 
immobilization via various modes of functionalization including physical adsorption, 
cross-linking and covalent binding. One of the main problem faced with surface 
functionalization is that complicated procedures and extensive modifications are required 
to both the substrates and the growth factors. Pretreatment of the surfaces is usually 
needed before producing the required surface functionalization effect, however surface 
pretreatment may alter and affect the integrity of a substrate [70]. Similarly most growth 
factors require certain chemical modification before they can be conjugated onto the 
implant material [66, 67]. For example, VEGF is oxidized with periodate before grafting 
onto dihydrazide modified PLGA [67]. However the bioactivity of growth factors may be 
compromised after chemical modification which could adversely affect their ability to 
bind to their respective cell surface receptors and hence disrupt their biological functions 
[71]. The two oxidized human VEGF isoforms, VEGF165 and VEGF121 have been 
reported to lose their binding properties to VEGF cell surface receptors [71]. Hence facile 
and effective functionalization procedures without altering the beneficial effects of the 
implant materials and growth factors should be used whenever possible. With each 
additional modification, the risk of compromising the integrity of the implant and 
bioactivity of the growth factors increases. To validitate the various surface modification 
procedures and integrity of the substrates, the chemical composition of the surfaces was 
checked by XPS. The increase in the C 1s and N 1 s and a concomitant decrease in the Ti 
2p peak intensity (Fig.3.6(C,D)) showed the successful deposition of the dopamine and 
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glutaraldehyde layers. Successful anchoring of the growth factor on the Ti substrate was 
indicated by an increase in the N content as shown in Table 3.1, due to the abundance of 
















86% 0.677 > 30% after 1 
month 








52% 0.841 Nil Immobilized Two steps 
 
Table 3.2 Summary of the various parameters of the functionalization process for the 
bioconjugation of VEGF with Titanium.  
 
 A summary of the binding efficiency, cytotoxicity, VEGF release profile and 
number of steps required for the fabrication of the substrates is listed in Table 3.2. As 
shown in Table 3.2 although physical adsorption had the highest rate of binding however 
there was also uncontrolled release of the factors from the substrate which may be 
undesirable [72-74]. A measurement of the percentage of VEGF released into the 
solution over a 30 day period showed that more than 30% of the factors were released. A 
number of studies have examined simple coating or loading of VEGF onto implants [72-
78] in order to provide local and sustained delivery of VEGF after implantation. However 
with this strategy some studies showed an uncontrolled initial burst in the release kinetics 
of VEGF from such implants [72-74]. High levels of VEGF in the local 
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microenvironments of these implants may be detrimental to healing and may promote the 
formation of malformed vessels [79]. To avoid the deleterious effects, secure 
immobilization strategy to promote angiogenesis would be preferred [64, 67-69]. 
Immobilization of growth factors on implants have been shown to promote desirable cell 
substrate interactions and enhance cell functions [65, 66]. Furthermore it has been 
demonstrated that immobilized VEGF is more effective in promoting proliferation of 
endothelial cells compared to soluble VEGF [68]. Both immobilized and soluble VEGF 
bind to receptors on cells, however they have differing effects due to the fact that soluble 
VEGF is internalized and subsequently degraded, while immobilized VEGF inhibits 
internalization and prevents down regulation [67, 80], thereby enabling the VEGF to 
stimulate proliferation for an extended period of time. A comparison of cross-linking and 
covalent binding shows that they come quite close in terms of binding efficiency and 
there is no release of growth factors into the solution which is the preferred methodology.  
However from our cytotoxicity tests (Table 3.2) we found that there is a lower cell 
viability with glutaraldehyde cross-linking compared to the other groups. This may be 
due to the fact that glutaraldehyde is known to be toxic and is able to kill cells quickly by 
cross-linking with their proteins. There have also been reports of its toxicity implicated in 
poor cell growth, attachment and apoptosis [56-58] by other groups. Although 
glutaraldehyde cross-linking effectively anchors a high density of VEGF onto the Ti-
GLU substrate surface and the molecules are also more firmly attached than those which 
are physically adsorbed however the associated toxicity has made it unsuitable for our 
study. The use of covalent immobilization with polydopamine looks promising. 
Polydopamine has been found to be able to form thin adherent films onto a wide variety 
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of metallic substrates via covalent bonds and various strong intermolecular interactions 
including metal chelation, hydrogen bonding and π-π interactions [62] which cannot be 
disrupted by normal mechanical forces. The use of this bioreactive layer for covalent 
bioconjugation with bioactive factors for orthopaedic applications holds great potential. 
However research on the effect of polydopamine in this area is still very limited, hence 
we will go on to further evaluate the efficacy of its use. 
 
3.5  Conclusion 
 Therefore because of the concerns of glutaraldehyde cross-linking which may 
have associated cytotoxicity and an additional step is required, we found that surface 
functionalization using covalent immobilization with polydopamine would be a more 
suitable methodology for our study. This would provide us with a facile and efficient 
method of attaching bioactive molecules to implant materials without the risk of 
uncontrolled adverse effects of unwanted ectopic bone formation, undesirable effects at 
locations beyond the implant site in the body and associated cytotoxicity. In the next 
chapter we will go on to investigate in greater detail the effects of such functionalized 












4.1  Effects of Surface Functionalized Titanium on Revascularization 
 
 
 Using the methodology developed in the previous chapter, we went on to 
characterize the physical structure and to investigate the effects of such functionalized 
substrates in greater detail.  
 
Osseointegration 
 One of the most important process in determining the success of an orthopaedic 
implant is osseointegration. Osseointegration is defined as the formation of a direct 
structural and functional connection between the living bone and the surface of a implant 
[81, 82]. An implant is considered osseointegrated if there is no progressive relative 
movement between the implant and the bone it has direct contact with [82]. Under ideal 
conditions, implants could permanently become incorporated within the bone and persist 
under all normal conditions of loading, that is the two could not be separated without 
fracture. Vascularization which is the provision of blood supply is a critical component 
for the process of osseointegration. The differentiation of osteogenic cells is highly 
dependent on tissue vascularity and ossification is closely linked to the vascularization of 
differentiating tissue [82]. Therefore the success of tissue healing, regeneration and 
integration lies in the key process of revascularization which is crucial in improving the 







Vascular endothelial growth factor (VEGF) 
 
 Bone healing around implants involves a cascade of cellular and biological events 
that take place at the bone-implant interface until finally the entire surface of the implant 
is covered by newly formed bone. This cascade of biological events is regulated by 
differentiation of cells stimulated by growth factors secreted at the bone-implant interface 
[82]. There has been considerable interest in modifying implant surfaces with growth 
factors to improve their cell functions and tissue integration capacity at the bone-implant 
interface. Enhanced cell functions and cell substrate interactions have been demonstrated 
with growth factors immobilized onto bioimplants [39-41]. One of the more important 
growth factors for stimulating neovascularization (i.e. formation of new blood vessels) in 
target areas [85] would be angiogenic growth factors, crucial in improving the successful 
integration of implants both in vitro and in vivo [83, 84]. Of these angiogenic factors, 
VEGF is the most potent and widely used key regulator of neovascularization [85, 86]. 
[85, 86]. VEGF is a crucial factor in not only angiogenesis regulation but also in 
osteoblast [87] and osteoclast function [88-90] during bone repair. VEGF acts directly on 
osteoblasts, promoting cell functions such as proliferation, migration and differentiation 
[91, 92]. In addition, VEGF also indirectly affect osteoblasts via its influences on 
endothelial cells [93, 94]. VEGF is known to induce endothelial cells in surrounding 
tissues to migrate, proliferate and form tubular structures [95] and is an essential survival 
factor for endothelial cells [93] and new vessel formation [96]. Endothelial cells are 
needed to provide complex interactive communication networks in bone for gap junction 
communication with osteoblasts crucial to their formation from osteoprogenitors [97]. 
Furthermore VEGF stimulates endothelial cells in the production of beneficial bone 
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forming factors acting on osteoblasts [92]. In all, the effects of VEGF on osteoblasts, 
osteoclasts and endothelial cells may synergistically act to enhance bone formation. 
 
Titanium alloy 
 Titanium alloy was the choice of substrate for this study as it is one of the most 
extensively used metal in orthopaedic implants especially in non-weight-bearing surface 
components such as femoral necks and stems [9]. Titanium has good mechanical 
properties, chemical stability and a naturally formed oxide layer on its surface which 
further increases its biocompatibility [10]. Titanium has inherent bioactivity to 
osseointegrate [10], however this is still not sufficient to truly and reliably incorporate 
into living bone [11]. Therefore enhancing vascularity in Titanium implants would be of 
great benefit in improving bone-implant anchorage and clinical results. 
 
Clinical need 
 There are clinical situations where compromised vascularity in the immediate 
vicinity of an implant leads to impaired fracture healing, which can result in implant 
failure. One commonly encountered example of such a problem is in high grade long 
bone fractures associated with significant surrounding soft tissue damage, where the 
blood supply to the fracture site can be greatly affected. This often leads to either delayed 
or non-union of the fracture, which can persist despite fracture fixation with orthopaedic 
devices. In time the non-healing fracture places high stresses on the implant and this can 
result in mechanical implant failure. Another clinical situation in which bone quality can 
be compromised leading to implant loosening is in hip resurfacing of a femoral head. Hip 
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resurfacing is a relatively new surgical technique that is an alternative to hip replacement 
in selected patients; its advantages are that it involves much less resection of the patient’s 
native hip bone, and the preserved bone makes subsequent revision surgery less difficult. 
However hip resurfacing depends on the integrity of the underlying femoral head bone 
stock for implant support and success, and this can be affected by compromised 
vascularity of the femoral neck and head, either from the surgical procedure or from pre-
existing conditions such as avascular necrosis. In both of these cases, any advance in 
technology that can enhance revascularization in the salient anatomical regions would be 




Figure 4.1 Schematic figure of a hip resurfacing implant: hemispherical cobalt chrome 
alloy component capping onto the femoral head of the hip joint, with Titanium guide 
stem inserted in femoral neck region. The femoral neck is the region at risk of 
compromised vascularity. Arrows indicate area of compromised vascularity. 
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 Therefore in this chapter we assessed and evaluated the physical properties and 
the bioactivity of the VEGF functionalized substrates. We aim to use the scheme 
developed in chapter 3 as a means to promote angiogenesis in the host tissues 
surrounding the functionalized implant, thereby enhancing healing and integration of 
healthy bone tissue around the implant. The functionalization of implant materials in 
order to enhance biocompatibility and promote revascularization has great potential in 


















4.2  Materials and Methods 
Materials  
 Materials and methods specific to this chapter are described below. All other 
materials and methods used in this chapter are described in Chapter 3 (Materials and 
methods section).  
 FITC-conjugated polyclonal goat anti-mouse IgG antibody was purchased from 
AbD Serotec (UK). Unconjugated monoclonal mouse antihuman von Willebrand Factor 
(vWF) antibody and PECAM1 (CD31) were purchased from Abcam (UK). Mesenchymal 
Stem Cell Growth Medium Bulletkit PT-3001 were purchased from Lonza Walkersville, 
Inc. 
Preparation of substrates & covalent immobilization 
 The substrates were prepared as described in chapter 3. The substrates are denoted 
Ti (pristine Titanium), Ti-PDOP (polydopamine-grafted Ti) and Ti-PDOP-VEGF 
(VEGF-coated, polydopamine-grafted Ti) in subsequent discussions.  
Binding efficiency 





   Unmodified and modified Ti substrates were coated with platinum and the 
surfaces of the substrates were imaged using a scanning electron microscope (SEM) 
(JEOL, model 5600LV). Surface roughness (Ra) was calculated from the roughness 
profile determined by atomic force microscopy (AFM) (Nanoscope III, Digital 
Instruments, Santa Barbara, CA). These analyses were performed in the tapping mode 
with a scan rate of 0.5-1 Hz. 
Cell culture 
 HDMECs (Lonza Walkersville, Inc) were cultured in endothelial cell growth 
medium MV and passage 5 HDMECs were used for the analysis of attachment and 
proliferation studies. hMSCs (Lonza Walkersville, Inc) were cultured in mesenchymal 
stem cell growth medium and passage 2 hMSCs were used for the in vitro analysis of the 
biological activity of the immobilized VEGF. The cells were incubated at 37 °C in a 
humidified atmosphere of 5% CO2 with the growth medium changed every 2-3 days. 
Attached cells were detached by trypsinization and resuspended in fresh culture medium 
for subsequent experiments described below.  
 
Cytotoxicity assay 






 Cell attachment on the various Titanium substrates was evaluated by counting the 
number of attached cells 12 hours after cell seeding. The substrates were placed into a 24-
microwell plate (Nalge, Nunc International) and seeded with HDMECs at a density of 
5 000 cells/cm2.  The number of attached cells on Ti, Ti-PDOP, Ti-PDOP-VEGF and the 
bottom of a culture well (control) was evaluated. At the time of cell counting, unattached 
cells were rinsed off with PBS. Adherent cells were then detached by trypsinization and 
counted using a haemocytometer. Cell proliferation on the substrates was evaluated by 
counting the number of attached cells on days 1, 7, and 14. The number of attached cells 
on the bottom of a similar culture well without any Titanium substrate was counted at the 
respective points in time and was used as a control. At each designated point in time, the 
unattached cells were rinsed off with PBS and the attached cells were trypsinized and 
counted using a haemocytometer. The number of attached cells is reported as number of 
cells/cm2. 
 
Biological activity of VEGF 
 In vitro angiogenesis assay was performed using 50 µl of BD Matrigel in each 
well of a 96-microwell plate (Nalge, Nunc International) at 4oC [98-100]. The matrigel 
was left at room temperature for 1 hr to allow it to solidify before use. hMSCs grown on 
the substrates for 2 weeks were detached with trypsin and the trypsin was removed by 
centrifugation. The cells were resuspended in normal cell culture medium and 2,000 cells 
in 50 µl of medium were plated onto the matrigel. The cells were then incubated for 3 hrs 
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and the capillary-like tube formation was observed under a light microscope (Olympus 
IX71).  
 
Immunofluorescent (IF) microscopy 
 
hMSCs grown on the substrates for 2 weeks were detached and plated on cover 
slips overnight. Cells plated on the cover slips were fixed in methanol at -20oC for 10 min 
and then rinsed with PBS, following which the cells were incubated with vWF or CD31 
staining (1:300) for 1 h, rinsed in PBS and further stained with FITC-conjugated goat 
anti-mouse secondary antibody (1:300) for 1 hr. The cells were then viewed using a 
fluorescent microscope (Olympus IX71). 
Statistical analysis 
 At least three samples per time point for each experimental condition were used. 
The data were tested for normal distribution by Shapiro-Wilk test. One-way analysis of 
variance (ANOVA) post-hoc Tukey test was used to assess the normally distributed data 













4.3  Results 
 
Determination of bioconjugation 
 The amount of VEGF bound to the  coated substrates was determined by ELISA 
kit to be 8.2 ± 2.0 ng/cm2 (66%) at a loading of 12.5ng, 14.3 ± 2.0 ng/cm2 (57%) at a 
loading of 25ng, 26.7 ± 3.0 ng/cm2 (53%) at a loading of 50ng, 39.1 ± 4.0 ng/cm2 (39%) 
at a loading of 100ng and 63.6 ± 5.0 ng/cm2 (25%) at a loading of 250ng. The results is 
summarized in table 4.1. Loading at 1µg/ml would provide the optimal binding rate, 










Percentage bound over 
absolute quantity loaded 
12.5 0.25 8.2 ± 2.0 66% 
25 0.5 14.3 ± 2.0 57% 
50 1  26.7 ± 3.0  53% 
100 2 39.1 ± 4.0 39% 
250 5 63.6± 5.0 25% 
 
Table 4.1 Binding optimization of Titanium with VEGF. Loading at a concentration of  1 






 The XPS wide scan spectra of the pristine Ti, Ti-PDOP, and Ti-PDOP-VEGF and 
their corresponding surface elemental compositions are shown in Table 4.2 and Fig. 4.2 
respectively. In the wide scan spectrum of the pristine Ti (Fig. 4.2(a)), the predominant 
components are C 1s (285 eV), Ti 2p (460 eV) and O 1s (530 eV). Successful deposition 
of polydopamine on the Ti substrate was indicated by an increase in the N and C contents 
as shown in Table 4.2. Nitrogen-to-carbon (N/C) ratios is 0.126 on Ti-PDOP which is 
similar to the theoretical N/C of 0.125 for dopamine. Furthermore, complete suppression 
of photoelectron peaks unique to Ti 2p (about 780 eV) confirms formation of the 
polydopamine thin film (Fig. 4.2(b)), while successful deposition of the growth factor on 
the Ti substrate was indicated by an increase in the N content. The changes in the surface 
atomic ratio of the functionalized substrates are quantified and summarized in Table 4.2. 
 
Substrate C% N% O% Ti% 
Ti 36.6 1.3 49.7 12.4 
Ti-PDOP 72.0 9.1 18.9 - 
Ti-PDOP-VEGF 68.6 13.5 17.8 - 
 
Table 4.2 Elemental Composition* at the Surface of Pristine and Ti -PDOP and Ti-
PDOP-VEGF substrates as determined by XPS. 
 





Figure 4.2 XPS wide-scan spectra of (A) pristine Ti, (B) Ti-PDOP and (C) Ti-PDOP-
VEGF to determine the chemical composition of the surfaces at each stage of 
modification. 
 
Surface structure by SEM 
 SEM investigations revealed the differences in the structure between the 
unmodified  pristine Ti and the modified Ti-PDOP-VEGF substrates (Fig. 4.3). 
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Figure 4.3 SEM images of (A) pristine Ti, (B) Ti-PDOP and (C) Ti-PDOP-VEGF  
substrates with different surface properties. 
 
Surface texture by AFM 
Surface roughness as determined by AFM (Fig. 4.4) was 147 ± 25 nm, 349 ± 




Figure 4.4 AFM images of (A) pristine Ti, (B) Ti-PDOP, (C) Ti-PDOP-VEGF substrates. 





 From the results (Fig. 4.5) approximately 63% of the cells seeded were attached 





cells were attached, indicating an increase of about 20% over the pristine substrates. Cell 
proliferation progressed steadily over 14 days of culture on the controls, pristine Ti, Ti-
PDOP and the Ti-PDOP-VEGF substrates as shown in Fig. 4.6.  
 
Figure 4.5 Number of adherent HDMECs per cm2 on surfaces of control, pristine Ti, Ti-
PDOP and Ti-PDOP-VEGF substrates (n=5). There is about a 20% increase in HDMEC 
attachment on the Ti-PDOP-VEGF over the pristine Ti. (*) denote significant differences 




Figure 4.6 Comparison of HDMEC proliferation over 2 weeks on surfaces of control, 
pristine Ti, Ti-PDOP and Ti-PDOP-VEGF substrates by counting the number of attached 
HDMEC on each type of substrate on days 1, 7 and 14 (n=5). There was approximately a 
2 fold increase in cell number on the Ti-PDOP-VEGF substrates compared to the pristine 
Ti. (*) denote significant differences (P < 0.05) compared with the pristine Ti. 
 
Cytotoxicity assay 
 As shown in Fig. 4.7, significantly higher viability of HDMECs was observed on 





Figure 4.7 Cell viability measured by MTT assay on the control, pristine Ti, Ti-PDOP 
and Ti-PDOP-VEGF substrates after 1 week (n=5). The assay shows that the substrates 
do not affect cell viability and there is significantly higher viability of HDMEC observed 
in the Ti-PDOP-VEGF compared to the pristine Ti. (*) denote significant differences (P 
< 0.05) compared with the pristine Ti. 
 
In vitro analysis of the biological activity of VEGF 
 Ti and Ti-PDOP-VEGF substrates for 2 weeks were plated onto a Matrigel 
surface. Capillary networks were observed on the hMSCs grown on Ti-PDOP-VEGF 
substrates (Fig. 4.8a) while hMSCs grown on pristine Ti remained as isolated, single cells 
on the Matrigel (Fig. 4.8b). The differentiated cells expressed strong vWF and weak 
CD31 after 2 weeks of VEGF mediated differentiation. 
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Figure 4.8 hMSCs grown on Ti-PDOP-VEGF substrates display a capillary network 
formation on Matrigel (A). hMSCs grown on pristine Ti substrates remain as isolated, 





Figure 4.9 hMSCs immunofluorescent staining reveals that the hMSCs derived cells 










4.4  Discussion 
 The fixation of prosthetic components to the bone can be done with or without 
bone cement. In the cemented technique PMMA is used to "glue" the metal to the bone. 
In direct biological fixation, precise bone cuts are required to achieve maximum contact 
between metal and bone. The advantage of cement fixation is that the prosthetic 
components are instantly fixed, allowing movement immediately after surgery. However 
in the instances where revision surgery is required, it is extremely difficult to chip out all 
the cement during implant replacement. Cement fixation is usually employed on elderly 
patients over sixty-five where their bone stock is more osteoporotic with less likelihood 
of growing into the prosthesis and chances of revision is lower due to less demands on 
the implant and shorter remaining life expectancy compared to younger patients.  Direct 
biological fixation is generally used for young patients due to better bone stock and 
ingrowth potential. The disadvantage of biological fixation is that it can take weeks or 
months to be fully complete during which weight bearing activity is restricted. However 
the final fixation achieved is more natural with complete incorporation of implant within 
the bone in ideal situations. Furthermore in young patients the chances for future revision 
surgery is higher and it would be easier to revise a cementless prosthesis without the need 
for cement removal. Another problem perceived was that cementless Titanium stems 
have been reported to be more resistant to osteolysis and mechanical failure compared to 
similar cemented Titanium stems [101]. The features of Titanium that are detrimental to 
the cement environment seems to have no effects in the cementless environment and may 
in fact be beneficial leading to different in performances of the two techniques. Therefore 
the enhancement of the bone implant interface especially in direct biological fixation with 
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Titanium implants would be extremely useful. This would greatly reduce the lag period in 
which osseointegration occurs between the prosthesis and the patient's bone.  
 To achieve this, VEGF was immobilized onto the surface of Titanium substrates. 
The biological activity of VEGF plays a dominant role during neovascularization of an 
implant in vivo and endothelial cells will come into direct contact with the implant 
surface [75]. Therefore HDMEC was used for the investigation because of their dominant 
role in revascularization and they are found predominantly in the area surrounding the 
implant [75, 102]. As cell attachment is the single most important factor during cell-
implant interactions [103], and is critical in determining the initial success of a 
bioengineered implant, therefore we investigated the effects of the functionalized 
substrates on cell adhesion. An increase of about 20% cell adhesion was observed with 
the Ti-PDOP-VEGF substrates (Fig. 4.5) compared to the pristine Ti. This suggests that 
the surface-immobilized VEGF is able to enhance cell attachment and may increase the 
affinity for endothelial cells to form a protective monolayer layer on the surface, where 
further cellular developments can occur. This observation is consistent with other 
reported studies where substrates immobilized with VEGF [68, 104] were shown to result 
in higher cell density. 
 The availability of the immobilized VEGF on the substrate surface to stimulate 
appropriate cellular responses is of crucial importance. Therefore, the growth of 
HDMECs was accessed at various time points over 2 weeks. The cell proliferation rates 
were not significantly different on the pristine Ti, Ti-PDOP substrates and in the controls 
on culture wells. However on the Ti-PDOP-VEGF substrates cell proliferation rate was 
markedly increased from day 7 to 14 and we can see significantly higher proliferation 
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rates and cell numbers compared to the pristine Ti and control culture wells. The cell 
number on day 14 was approximately 2-fold higher on the Ti-PDOP-VEGF substrates in 
comparison to the pristine Ti and control culture wells. This finding indicates that the Ti-
PDOP-VEGF substrate immobilized with VEGF promotes greater proliferation. The 
effect of proliferation observed in the Ti-PDOP-VEGF substrates was likely due to the 
immobilized VEGF providing a controlled and sustainable effect on the endothelial cell 
functions. Immobilized growth factors can regulate and guide local cell functions, 
simulating a local microenvironment in vivo [85, 105]. The continuous stimulated growth 
of the endothelial cells by the immobilized VEGF over 14 days is in line with the 
observations by other groups that immobilized VEGF can provide extended signaling to 
the endothelial cells and is able to continuously stimulate their growth without down-
regulation by receptor/ligand complex internalization [106-109].  
 Cell viability on the pristine Ti, Ti-PDOP and Ti-PDOP-VEGF substrates was 
assessed using the MTT assay, to give an indication of the effect of the substrates on the 
survival and proliferation of the attached cells after 1 week of culture. As shown in Fig. 
4.6, significantly higher viability of HDMECs was observed on the Ti-PDOP-VEGF 
substrates compared to both the pristine Ti and culture wells controls. The results suggest 
that Ti-PDOP-VEGF substrates are not cytotoxic to the cells, and the immobilized VEGF 
on its surface can promote the survival and proliferation of HDMECs. These observations 
can be explained by similar findings seen by other groups where immobilized VEGF 
enhanced the survival of endothelial cells through interactions with integrin receptors 
[110] and signal transduction pathways [93]. To ensure that the survival and proliferative 
effects of VEGF observed was not because of the immobilized VEGF being released into 
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the culture medium, HDMECs was cultured on a permeable support (0.4 μm pore size, 
Costar®, Corning) in transwells with or without substrates immobilized with VEGF 
placed at the bottom of the wells for 2 weeks. No significant difference was observed in 
cell attachment, cell proliferation and cell viability tests (data not shown) between the 
two groups. Hence it can be concluded that the enhancement in endothelial cell functions 
observed with the Ti-PDOP-VEGF substrates is due to the immobilized VEGF and not 
VEGF released into the culture medium.  
 Polydopamine conjugation of VEGF may affect its biological functions, therefore 
to show that the immobilized VEGF retained its bioactivity, we did a further test to 
confirm this. VEGF is known to cause the in vitro differentiation of mesenchymal stem 
cells into endothelial cells [111-113]. Based on this we carried out an in vitro model of 
angiogenesis to test the functional features of the differentiated endothelial cells. A 
hallmark of endothelial cells is their ability to undergo morphogenic changes to become 
tubular structures [100]. In vitro angiogenesis studies have shown that endothelial cells 
form a network of tubular structures when incubated on extracellular matrices such as 
matrigel [98-100]. The hMSCs purchased from Lonza, US, were positive for the markers 
CD 166, CD29 and CD44 and negative for typical endothelial markers, hence the 
possibility that the differentiated cells may have originated from a small population of 
endothelial progenitors is excluded. hMSCs grown on the pristine Ti and Ti-PDOP-
VEGF substrates for 2 weeks were plated onto a Matrigel surface. The formation of a 
capillary network on the hMSCs grown on Ti-PDOP-VEGF substrates was observed 3 h 
later (Fig. 4.8a). hMSCs grown on pristine Ti did not form any capillary network and 
remained as isolated, single cells on the Matrigel (Fig. 4.8b). To show that the 
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differentiated cells were indeed endothelial cells, endothelial cell markers vWF and 
CD31 [114, 115] were used to confirm this. As shown in Fig. 4.9 the differentiated cells 
expressed strong vWF and weak CD31 after 2 weeks of VEGF mediated differentiation. 
Thus, the results further confirmed that the VEGF immobilized on the polydopamine 
















4.5  Conclusion 
 In summary, we have shown that immobilization of angiogenic growth factors 
onto the surface of metal substrates may be a viable approach in promoting 
revascularization and enhanced implant integration in a controllable manner. By 
immobilizing VEGF onto a metal substrate using biomimetic polymer film, we 
demonstrated that the modified substrate promotes the survival and proliferation of 
endothelial cells and is able to induce the differentiation of hMSCs into endothelial cells. 
This enhanced recruitment and differentiation of cells and their progenitors to the target 
implant is beneficial in accelerating vasculature formation and new bone tissue formation. 
Thus, the coating of a biomimetic polymer film onto a metal substrate followed by VEGF 
conjugation provides a means for applications where revascularization around implants 
would be beneficial in tissue and bio-engineering applications. The method reported here 
of immobilizing VEGF onto metal substrates has the advantage of efficiency, ease of 
fabrication and possibly of usage on various types of materials without extensive surface 
preparation which reduces overall risk associated with the implant use in vivo. This may 
serve as a model for the immobilization of other growth factors onto various different 










5.1  Effects of Surface Functionalized Cobalt Chromium on Osteogenesis  
 Having determined a suitable model for the immobilization of VEGF onto 
Titanium alloy substrates in the previous chapter, we went on to investigate if this model 
is viable in another metallic alloy and with a different growth factor.  
 
Cobalt Chromium   
 Most metallic orthopaedic implants are currently made from a mixture of alloys 
[116]. Cobalt Chromium alloy (CoCr) is one of the other most used metal besides 
Titanium alloy due to its toughness, hardness (HV=350), strength, high wear and 
corrosion resistance [117]. However CoCr does not osseointegrate well, there is a 
tendency for the formation of an intervening fibrous layer between the bone-implant 
interface. In clinical situations this compromised bone growth in the immediate vicinity 
of an implant leads to weakened bone quality and can result in implant failure. One 
encountered example of such a problem is in the acetabular component (typically made 
of CoCr) of a hip implant (Fig. 5.0), where the patient loses bone in the pelvis area. In 
this instance, enhancing bone growth would be of great benefit in improving clinical 
results and reducing complications and patient morbidity. 
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Figure 5.1 Bone loss in acetabular component (made of CoCr) of a hip implant 
 
Bone morphogenic proteins 
 Coating implants with growth factors such as bone-morphogenetic proteins 
(BMPs) may be a solution to enhance and accelerate the quality of osseointegration [118, 
119]. Bone-morphogenetic protein 2 (BMP2) has been shown to be particularly effective 
in enhancing bone formation [120, 121]. BMP2 plays a major role during skeleton and 
cartilage formation and the maintenance of homeostasis during bone remodeling. BMP2 
is also known to be involved in the processes of differentiation, calcification and binds to 
BMP2 receptors on osteoblastic cells stimulating ALP activity [42]. To date only BMP2 
and bone-morphogenetic protein 7 (BMP7) have been approved for use by the Food and 
Drug Administration (FDA) in specific orthopaedic applications [122].  
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 Therefore in this study we aim to functionalize CoCr with BMP2 using the 
methodology developed in chapter 3. An aqueous dopamine solution at pH 8.5 was used 
to create a thin layer of adherent polydopamine surface on the CoCr substrates via 
autopolymerization [123]. This reactive layer contains catechol and quinone functional 
groups which can be used for covalent coupling to nucleophiles [62]. The effects of the 
functionalized substrates on the enhancement of bone growth were then investigated. The 
biological activities of the immobilized BMP2 were analyzed with osteoblastic cells 
(MC3T3-E1). MC3T3-E1 was used here as osteoblastic cells are usually found in the 
peri-implant area and these cells migrate to the implant interface, adhere, proliferate and 














5.2  Materials and Methods 
Materials 
 Cobalt Chromium alloy foils (denoted as CoCr in the subsequent discussion) were 
purchased from Goodfellow Inc. of Cambridge, UK. Osteoblastic cells (MC3T3-E1 
subclone 14) were obtained from American Type Culture Collection. The 
QuantiChromTM alkaline phosphatase (ALP) assay kit and QuantiChromTM Calcium 
Assay Kit were purchased from BioAssay Systems. 
Preparation of substrates 
 CoCr foils were cut to a size of 10 mm × 10 mm. The substrates were polished 
using 600 and 1200 grid sandpaper and then sonicated for 10 min in water. The carbide 
deposited during polishing were removed by sonicating the substrates in Kroll’s reagent 
(4.0% HF, 7.2% HNO3, 88.8% water) for 10 min. The reaction was terminated by the 
addition of 1 N sodium hydroxide. The substrates were then cleaned ultrasonically for 10 
min each in dichloromethane, acetone, and water and placed in 40% HNO3 for 40 min for 
surface passivation. The acid-treated substrates were then rinsed thoroughly with water. 
Polydopamine was anchored to the surface of the CoCr substrates, via immersion of the 
substrates in a 2 mg/ml solution of dopamine (10 mM Tris buffer, pH=8.5) overnight in 
the dark.[62, 123] The substrates were then rinsed with copious ultrapure water to 
remove the unattached dopamine and dried under nitrogen flow. The polydopamine-
grafted CoCr substrates were then coated with BMP2 at concentration of 1 µg/ml  and 
10µg/ml and incubated overnight in a humid atmosphere at room temperature [62, 63]. 
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The substrates were then washed three times with sterile PBS to remove unattached 
BMP2 and left to air dry in a sterile environment before use. The substrates are denoted 
as CoCr (pristine cobalt chrome), CoCr-PDOP (polydopamine-grafted CoCr) and CoCr-
PDOP-BMP2 (BMP2 coated, polydopamine-grafted CoCr) in subsequent discussions.  
 
Binding efficiency 
 To determine the binding efficiency of the surface functionalization procedures, 
the quantity of BMP2 in the loading solution and the combined washing solution was 
performed using an enzyme-linked immunosorbent assay kit (BMP2 ELISA, R&D 
System, Minneapolis, MN) according to the manufacturer's instructions. The surface 
density of bound BMP2 was calculated from the difference between the initial and 
remaining BMP2 in the washing buffer. 
Characterization 
 XPS and SEM-EDX analysis was carried out as described in Chapter 3 (Materials 
and methods section). 
Cytotoxicity assay 




MC3T3-E1 were cultured in alpha minimum essential medium (Invitrogen, USA) 
supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml 
streptomycin. Passage 5 MC3T3-E1 was used for the studies. The cells were incubated at 
37 °C in a humidified atmosphere of 5% CO2 with the growth medium changed every 2-3 
days. Attached cells were detached by trypsinization and resuspended in fresh culture 
medium for subsequent experiments described below.  
 
Cell adhesion 
 Cell attachment on the various CoCr substrates was evaluated by measuring the 
number of attached cells with Vialight Cell Proliferation Assay Kit (Lonza Walkersville, 
Inc) 12 hrs after cell seeding. The substrates were seeded with MC3T3-E1 at a density of 
3 000 cells/cm2.  At the time of cell counting, unattached cells were rinsed off with PBS. 
ATP monitoring reagent in Tris Acetate buffer was prepared according to the 
manufacturer’s instructions and added to each sample and incubated for 5 min at room 
temperature protected from light. The emitted luminescence was then measured by using 
a luminometer (GloMax-96 Microplate Luminometer). A reference standard curve was 
created for converting the observed luminescence values into cell numbers.  
 
Alkaline phosphatase (ALP) activity assay 
 ALP activity was assessed using QuantiChromTM alkaline phosphatase assay kit 
according to manufacturer’s instructions. Cells were seeded onto the substrates at a 
density of 3000 cells/cm2 in a growth medium supplemented with 50 μg/ml ascorbic acid 
and 10 mM sodium β-glycerophosphate. At specific time intervals during cultivation, the 
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cell layers were washed with PBS and scraped off from the surfaces in cell lysis buffer 
and sonicated to disrupt the cell membranes. After sonication, cellular debri was removed 
by centrifugation and aliquots of the cell lysates were collected for analysis of ALP 
activity and quantification of total protein level. A 10 μl aliquot of the sonicated cell 
lysate was added to 190 μl of reagent solution containing 10 mM p-nitrophenyl 
phosphate and 5 mM magnesium acetate and the color intensity of the reaction mixture 
was measured at 405 nm at time zero and again after 4 min on an absorbance plate reader. 
The ALP activity of each sample was calculated according to a formula provided in the 
kit. ALP activity was normalized with respect to the total protein content obtained from 
the same cell lysate, and expressed as number of IU of p-nitrophenol formation per 
minute per gram of total proteins (IU min-1 g-1 protein). 
 
Calcium deposition  
 The amount of calcium deposited on the substrates by the cells after 3 weeks of 
culture was measured using QuantiChromTM Calcium Assay Kit according to 
manufacturer’s instructions. Briefly, the substrates were washed twice with PBS and 
soaked in 6 N hydrochloric acid overnight with shaking to dissolve the calcium content. 
The supernatants were then collected and 5 μl aliquot was added to 200 μl of working 
solution of the kit. After incubation for 3min, the absorbance was measured at 612nm on 
an absorbance plate reader. A Ca2+ standard curve calibrated using known Ca2+ 





At least three samples per time point for each experimental condition were used. The 
results are reported as mean ± SD and one-way analysis of variance (ANOVA) with 
Tukey-Kramer post-hoc test was used to assess the normally distributed data. Statistical 





























 5.3 Results 
 
Determination of bioconjugation 
 The amount of BMP2 bound to the  coated substrates was determined by ELISA 
kit to be 7.7 ± 2.0 ng/cm2 (62%) at a loading of 12.5ng, 13.6 ± 2.0 ng/cm2 (54%) at a 
loading of 25ng, 23.0 ± 3.0 ng/cm2 (52%) at a loading of 50ng, 37.3 ± 4.0 ng/cm2 (37%) 
at a loading of 100ng, 59.2 ± 5.0 ng/cm2 (24%) at a loading of 250ng and 108.5 ± 12.0 
ng/cm2 (22%) at a loading of 500ng. Loading at 1µg/ml would provide the optimal 
binding rate, however because high density BMP2 is needed for osteogenesis, therefore 
another concentration 10µg/ml was used for the fabrication of the CoCr-PDOP-BMP2 










over absolute quantity 
loaded 
12.5 0.25 7.7 ± 2.0 62% 
25 0.5 13.6 ± 2.0 54% 
50 1 23.0 ± 3.0 52% 
100 2 37.3 ± 4.0 37% 
250 5 59.2± 5.0 24% 
500 10 108.5±12.0 22% 
 






 SEM-EDX was used to characterize the CoCr substrates obtained from the 
manufacturer to check for the uniformity and quality of the alloy obtained. From the 
results (Fig. 5.1a) approximately 70% of the substrates consist of the element Co and 
30% consist of the element Cr, uniformly distributed which conforms to the requirements 








The XPS wide scan spectra of the pristine CoCr, CoCr-PDOP and CoCr-PDOP-
BMP2 and their corresponding surface elemental compositions are shown in Table 5.1 
and Fig. 5.3  respectively. In the wide scan spectrum of the pristine CoCr (Fig. 5.3(A)), 
the predominant components are C 1s (285 eV), O 1s (530 eV) and Co 2p (780 eV). 
Successful deposition of polydopamine on the CoCr substrate was indicated by an 
increase in the N and C contents while successful deposition of the growth factor on the 
CoCr substrate was indicated by a further increase in the N content. The changes in the 
surface atomic ratio of the functionalized substrates are quantified and summarized in 
Table 5.1. 













71.2 9.5 19.3 - 
CoCr-PDOP-
BMP2(10µg/ml) 
69.1 11.7 19.2 
- 
 
Table 5.1 Elemental Composition* at the Surface of Pristine and CoCr -PDOP and CoCr-
PDOP-BMP2 substrates as determined by XPS 
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Cell adhesion 
 From the results (Fig. 5.4) cellular adhesion on the CoCr-PDOP-BMP2 (10 µg/ml) 
substrates was significantly higher than that on the pristine CoCr. There is approximately 
2-fold increase in the number of cells attached to the CoCr-PDOP-BMP2 (10 µg/ml)  
substrates compared to the pristine CoCr. 
 
Figure 5.4 Number of adherent MC3T3-E1 per cm2 on surfaces of pristine CoCr, CoCr-
PDOP, CoCr-PDOP- BMP2 (1 µg/ml) and CoCr-PDOP-BMP2 (10 µg/ml) substrates 
(n=3). (*) denote significant differences (P < 0.05) compared with the pristine CoCr. 
 
Cytotoxicity 
 Cell viability was assessed using MTT assay to investigate the cytotoxic profile of 
the different substrates. As shown in Fig. 5.5, MC3T3-E1 seeded on the CoCr-PDOP- 
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BMP2 (10 µg/ml).substrates showed significantly higher viability compared to both the 
pristine CoCr and CoCr-PDOP substrates. 
 
Figure 5.5 Cell viability measured by MTT assay on the control, pristine CoCr, CoCr-
PDOP, CoCr-PDOP- BMP2 (1 µg/ml) and CoCr-PDOP-BMP2 (10 µg/ml).substrates 
after 1 week (n=3). 
 
ALP assay & calcium deposition assay 
ALP activity was measured after the cells were cultured for 1 and 2 weeks on the 
substrates. Calcium deposition was measured after the cells were cultured for 3 weeks on 
the substrates. The choice of the different time points is due to the fact that ALP usually 
peaks before mineralization actually begins [125]. From Fig. 5.6 & Fig. 5.7, it can be 
seen that ALP activity and calcium deposition of the CoCr-PDOP-BMP2 (10 µg/ml). 
substrates were significantly higher than those on the pristine CoCr, CoCr-PDOP and 
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CoCr-PDOP-BMP2 (1 µg/ml) substrates. There is roughly a 2-fold increase in ALP 
activity after 2 weeks of incubation and a 3-fold increase in calcium content after 3 weeks 
of incubation in CoCr-PDOP-BMP2(10 µg/ml) substrates compared to the pristine ones.  
 
Figure 5.6 ALP activity of MC3T3-E1 seeded on pristine CoCr, CoCr-PDOP, CoCr-
PDOP- BMP2 (1 µg/ml) and CoCr-PDOP-BMP2 (10 µg/ml)substrates on week 1 and 2 
(n=3). (*) denote significant differences (P < 0.05) compared with the pristine CoCr. 
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Figure 5.7 Calcium deposition of MC3T3-E1 seeded on pristine CoCr, CoCr-PDOP, 
CoCr-PDOP-BMP2 (1 µg/ml) and CoCr-PDOP-BMP2 (10 µg/ml) substrates on week 3 













  Cobalt Chromium alloys are currently one of the most popular implant materials 
used in orthopaedics [126]. However due to its lack of osseointegrative properties, 
implant improvements conferring enhanced bone growth would drastically improve 
clinical results and reduce peri and post-operative complications and patient morbidity. 
BMP2 is known to induce bone and cartilage formation and plays a key role in osteoblast 
differentiation. Therefore in this study we determined the effects of CoCr functionalized 
with BMP2 on osteoblastic cells. To validitate the functionalization procedures, the 
chemical composition of the surfaces at various stages of surface modification was 
determined by XPS. Successful deposition of polydopamine on the CoCr substrate was 
indicated by an increase in the N and C contents as shown in Table 5.1. Nitrogen-to-
carbon (N/C) ratios is 0.124 on CoCr-PDOP which is similar to the theoretical N/C of 
0.125 for dopamine. Complete suppression of photoelectron peaks unique to Co 2p 
(about 780 eV) confirms formation of the polydopamine thin film (Fig. 5.3(B)). 
Successful deposition of the growth factor on the CoCr substrate was indicated by a 
further increase in the N content. Two concentrations of BMP2 was used for the 
investigation as during the initial stages of the experiments, it was found that loading at a 
concentration of 1 µg/ml was not sufficient to elicit any significant responses, therefore 
an additional concentration at 10 µg/ml was used.  
 Attachment of cells onto the implant surface is a prerequisite for successful 
osseointegration and cell attachment assays (Fig. 5.2) showed that the CoCr-PDOP-
BMP2 (10 µg/ml) substrates had a significantly higher number of cells compared to the 
other groups. This suggests that immobilizing a high concentration of BMP2 was able to 
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enhance the initial cell attachment. This is in accord with other studies where 
immobilized BMP2 was able to increase the number of attached osteoblasts [127, 128]. 
Cytotoxicity assays did not show any significant differences among all the experimental 
substrate groups. Besides the initial cellular adhesion and material cytotoxicity, 
subsequent ALP activity and calcium deposition are important considerations for 
osseointegration. ALP activity is used as a marker for early differentiation of osteoblastic 
cells [129, 130] and was measured after the cells were cultured for 1 and 2 weeks on the 
various substrates. From Fig. 5.4 it can be observed that ALP activity of osteoblastic cells 
seeded on CoCr-PDOP and CoCr-PDOP-BMP2 (1 µg/ml)  is at a similar level as those 
found on pristine CoCr throughout the 2 weeks period. On the other hand, osteoblastic 
cells cultivated on the CoCr-PDOP-BMP2 (10 µg/ml) substrates have a significantly 
higher ALP activity. A high immobilized BMP2 density is able to increase the ALP 
activity of osteoblasts significantly which in turn indicates enhanced bone cell functions 
and matrix production. Calcium mineral deposition is a late bone differentiation marker 
for bone matrix formation [131]. The amount of calcium deposited after the cells were 
cultured for 3 weeks on the various substrates are shown in Fig. 5.7. As corroborated by 
the ALP activity, there is no significant difference in calcium deposition between pristine 
CoCr, CoCr-PDOP and CoCr-PDOP-BMP2 (1 µg/ml). However in the CoCr-PDOP-
BMP2 (10 µg/ml) substrates the calcium deposition was increased to about 3 fold, 
indications of a stimulating effect on matrix formation. In vitro work with BMP2 in 
soluble, free form have shown that it can stimulate early differentiation and matrix 
mineralization of osteoblastic cells [38, 41, 47, 132, 133]. However such an approach is 
not appropriate for implant applications, as there are concerns about the long-term effects 
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of released soluble growth factor on the fracture site and their non-specific distribution 
throughout the body via the bloodstream [134, 135]. The use of covalent immobilization 

















5.5  Conclusion 
 This study has shown that the immobilization of BMP2 on Cobalt Chromium has 
the ability to confer enhancement of cell-implant interactions between the originally inert 
substrate and osteoblastic cells, without demonstrable cell toxicity, resulting in enhanced 
bone matrix formation and bone growth. However the cost would be prohibitive for most 
patients, as huge quantities and a high immobilized BMP2 density would be needed and 
the problem is further aggravated by the short shelf lives of the growth factor. All these 
would pose significant problems for the usage of BMP2 in clinical applications, therefore 
















Chapter 6  
 
6.1  Growth Factor Versus Peptide 
 
 In the previous chapter the surface functionalization of BMP2 on CoCr substrates 
was achieved. However there are certain issues associated with the use of BMP2 
including the huge quantity of BMP2 needed to stimulate bone growth, it is expensive 
and has a short shelf life. Therefore we sourced for an alternative molecule as a viable 
replacement for BMP2. 
 
BMP Peptide 
 BMP2 plays integral roles in bone and cartilage formation and have been 
demonstrated to be promising in modulating bioimplant-cell interactions. However 
current BMP2 applications are limited in its usage, such as in cell culture supplements, 
with bone matrix materials such as collagen for enhanced osteoinduction, in recalcitrant 
non-union fractures and spinal fusion, albeit at hefty costs, to the tune of US$3500 
onwards [120, 136, 137].  Recent studies have reported the utility of BMP Peptides on 
effective induction of bone growth and accelerated bone healing [42, 43, 127]. BMP 
Peptides possess various advantages compared to BMP2, such as increased stability, 
incorporation at higher concentrations, and more significantly, lower costs [43]. Shelf 
lives of BMP Peptides are also significantly longer, as they can be stored in freeze-dried 
conditions for over 2 years, whereas BMP2 can only be stored for a short time, e.g. 6 
months at 4oC [43].  
 Therefore the objective of this study is to investigate the effects of CoCr 
substrates immobilized with BMP peptide on osteogenesis. Dopa polymerization was 
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used to create a thin reactive layer for covalent coupling with the BMP Peptide. The BMP 
Peptide is derived from residues 73-92 of BMP2 that is known to induce differentiation 
and mineralization of bone-marrow stromal cells [42]. The peptide was synthesized with 
a cysteine amino acid at the N-terminus using miniPEG (Fmoc-8-amino-3,6-
dioxooctanoic acid)  as the linker to produce a cys-tag functionalized BMP Peptide for 
site specific conjugation via thiol directed chemistry [109, 138]. Several approaches are 
available for the site-specific labeling and we have chosen the insertion of a cys-tag at the 
N-terminus to keep interference on the functional activities of the peptide to a minimum 
[138-140].   
 The effects of the functionalized substrates on the enhancement of osteogenesis 
were then investigated. The binding properties and efficiency of the biomimetic coating 
with BMP Peptide were evaluated and the biological activities of the immobilized BMP 
Peptide were analyzed with osteoblastic cells (MC3T3-E1). CoCr substrates immobilized 
with BMP2 were used as a basis of comparison here. We aim to use the above approach 
to provide an alternative viable cost effective solution compared to conventional BMP2 









6.2  Materials and Methods 
Materials 
 Materials and methods specific to this chapter are described below. All other 
materials and methods used in this chapter are described in Chapter 3 and 5 (Materials 
and methods section). 
 O-Phthaldialdehyde (OPA), 2-mercaptoethanol and Alizarin Red S were 
purchased from Sigma, USA. Rabbit polyclonal anti-phospho Smad1/5/8 were purchased 
from Millipore, USA. Goat anti-rabbit Alexfluor 488 and Phalloidin-Alexfluor 566 was 
purchased from Invitrogen, USA. DAPI containing mounting medium was purchased 
from Vectorlab, Canada.  
BMP Peptide  
           The cys-tag functionalized BMP Peptide, CKIPKASSVPTELSAISTLYL was 
obtained from 1st BASE Pte. Ltd. (Sg). The purity was 96.5%, as determined by reversed-
phase high-performance liquid chromatography (HPLC) on a Venusil XBP-C18 column 
with a 10-70% acetonitrile gradient in 0.1% trifluoroacetic acid in water, at a flow rate of 
1.0ml/min, with detection at 220 nm. Fmoc (9-fluorenylmethyloxycarbonyl) solid-phase 
peptide synthesis was employed and a miniPEG (Fmoc-8-amino-3,6-dioxooctanoic acid) 
was used as the linker for the cysteine amino acid at the N-terminus. 
Details 
Sequence :Cys-miniPEG-KIPKASSVPTELSAISTLYL 
Length  :20AA 
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Purity  :96.5% 
HPLC Report: 
Column : 4.6mm*250mm, Venusil XBP-C18 
Mobile phase :A=0.1% TFA/Acetonitrile, 
  :B=0.1%TFA/water, 
Gradient :   A  B 
  0.01min  23%  77% 
  25min   48%  52% 
  25.1min  100%  0% 
  30.0min  Stop 




Mass Spectrometry Report 
 
Item Parameter Item Parameter 
Probe: ESI Probe bias: +4.5kv 
Nebulizer Gas 
Flow: 1.5L/min Detector: 1.5kv 
CDL: -20.0v T.Flow: 0.2ml/min 
CDL Temp: 250oC B.conc 50%H2O50%ACN 




Preparation of substrates 
CoCr foils were prepared as described in chapter 5 (Materials and methods 
section). The polydopamine-grafted CoCr substrates were then coated with BMP2 (10 
μg/ml) or BMP Peptide (1000 μg/ml) dissolved in 10mM Tris buffer, pH=8.5 and 
incubated overnight in a humid atmosphere at room temperature [62, 63]. The substrates 
were then washed three times with sterile PBS to remove unattached BMP2 or BMP 
Peptide and left to air dry in a sterile environment before use. The substrates are denoted 
CoCr (pristine cobalt chrome), CoCr-PDOP (polydopamine-grafted CoCr), CoCr-PDOP-
BMP2 (10 µg/ml) (BMP2 coated, polydopamine-grafted CoCr) and CoCr-PDOP-BMP 
Peptide (1000 µg/ml) (BMP Peptide coated, polydopamine-grafted CoCr) in subsequent 
discussions. 
 
Determination of bioconjugation 
 O-Phthaldialdehyde (OPA) assay was used to verify the bioconjugation efficiency 
of BMP Peptide. OPA reacts with amino groups in the presence of thiol-containing 
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molecules such as 2-mercaptoethanol, generating a fluorescence product. Detection limits 
for proteins in liquid are in the μg/cm3 range [141]. A solution of 1ml borate buffer 
(50mM PH=9.2), 250 μl o-Phthaldialdehyde (OPA) (Sigma, USA, 20mg/ml) and 250μl 
2-mercaptoethanol (Sigma, USA) were added to the amino-group containing carrier and 
reacted for one hour at room temperature. After washing three times with 75% ethanol, 
the fluorescence marking by OPA were observed under a fluorescence microscope 
(Axioplan 4.4, Zeiss) using excitation wavelength of 360nm and emission wavelength of 
436 nm.   
Characterization 
 XPS, SEM and AFM analysis was carried out as described in Chapter 3 & 4 
(Materials and methods section). 
Cell culture 
 Cell culture were performed as described in Chapter 5 (Materials and methods 
section). 
Cellular adhesion 





The cell morphology of MC3T3-E1 cells were examined by detecting filamentous 
actin of the cytoskeleton by immunofluorescence. After seeding on the substrate for 48 
hours, MC3T3-E1 was washed with PBS three times and fixed with 4% 
paraformaldehyde. After permeabilizing with 0.2% Triton X-100 in PBS for 5 min the 
cells were incubated with phalloidin-rodamine (Invitrogen, CA) for 20 min and the 
nucleus counterstained with DAPI. The cells were then viewed using a fluorescent 
microscope (Olympus IX71). 
 
Cytotoxicity assay 





 Immunostaining with anti-phospho Smad1/5/8 was performed to evaluate BMP 
signaling via Smad-dependent pathways. Cells were seeded on the substrates for 24 hours 
before fixation with 4% paraformaldehyde. The primary antibody for immunostaining 
was rabbit polyclonal anti-phospho Smad1/5/8 (1:200 dilution; Millipore, USA). 
Secondary antibody was goat anti-rabbit Alexfluor 488 (Invitrogen, USA). Phalloidin-
Alexfluor 566 (Invitrogen, USA) was incubated with specimens for cytoplasm 
counterstaining. Cell nucleus was counterstained with DAPI containing mounting 






Alkaline phosphatase (ALP) activity assay & calcium deposition  
 ALP activity and calcium deposition were assessed as described in Chapter 5 
(Materials and methods section). 
Alizarin red staining 
Cells grown on the various substrates were stained with 1% alizarin red for 2 
minutes and then washed with PBS. The stained cells were then observed under a light 
microscope. 
Statistical analysis 
At least three samples per time point for each experimental condition were used. 
The results are reported as mean ± SD and one-way analysis of variance (ANOVA) with 
Tukey-Kramer post-hoc test was used to assess the normally distributed data. Statistical 


















Determination of equivalent functional dosages of  BMP Peptide to BMP2 
 Various concentrations of BMP Peptide and BMP2 was functionalized onto the 
CoCr substrates and a comparison of MC3T3-E1 proliferation over 7 days was tabulated. 
From the results (Fig. 6.1), immobilization of BMP Peptide at 1000 µg/ml would provide  
equivalent functional dosages of BMP2 at 10 µg/ml. 
 
Figure 6.1  Comparison of MC3T3-E1 proliferation over 7 days on surfaces of control, 
pristine CoCr, CoCr-PDOP-BMP Peptide and CoCr-PDOP-BMP2  substrates at various 
concentrations on days 1, 3 and 7 (n=3). 
 
Determination of bioconjugation of BMP Peptide 
There was no positive signal on the pristine CoCr substrate (Fig. 6.2). A positive 
green fluorescence signal can be seen with the polydopamine-coated CoCr substrates 
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after reaction with OPA. Further coating with BMP peptide significantly increases the 
intensity of the signal. 
 
Figure 6.2 OPA images of pristine CoCr, CoCr-PDOP and CoCr-PDOP-BMP Peptide 









Percentage bound over 
absolute quantity loaded 
CoCr Negative Control - 4.0±1 - 
CoCr-PDOP - 3.9±1 - 
CoCr-PDOP-BMP 0.05 6.8±2 98.6 
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Peptide 1 µg 
CoCr-PDOP-BMP 
Peptide 10 µg 0.5 8.7±2 97.1 
CoCr-PDOP-BMP 
Peptide 100 µg 5 12.0±3 95.3 
CoCr-PDOP-BMP 
Peptide 1000 µg 50 19.3±2 93.8 
 
Table 6.1 Binding Intensity of Cobalt Chromium with BMP Peptide as measured by 
ImageJ 1.44p Wayne Rasband, National Institutes of Health, USA. and converted to 

















 Significantly higher viability of MC3T3-E1 was observed on the CoCr-PDOP-
BMP2 (10 µg/ml)  and CoCr-PDOP-BMP Peptide (1000 µg/ml) substrates compared to 
both the pristine CoCr and CoCr-PDOP (Fig. 6.3). 
 
Figure 6.3 Cell viability measured by MTT assay on the pristine CoCr, CoCr-PDOP, 
CoCr-PDOP-BMP2 (10 µg/ml) and CoCr-PDOP-BMP Peptide (1000 µg/ml) substrates 










Immunostaining with anti-phospho Smad1/5/8 
 The cells were responsive to BMP stimulation as seen by the activation and 
phosphorylation of Smad1/5/8 transcription factors (Fig. 6.4). 
 
 
Figure 6.4 Confocal images of representative 3T3 cells on functionalized substrates. (A1-
A4) pristine CoCr; (B1-B4)CoCr-PDOP; (C1-C4)CoCr-PDOP-BMP2 (D1-D4)CoCr-PDOP-








Surface structure by SEM 
 SEM investigations revealing the structures of the pristine CoCr and the modified 
CoCr substrates (Fig. 6.5). 
 
Figure 6.5 SEM images of (A) pristine CoCr, (B) CoCr-PDOP, (C) CoCr-PDOP BMP2 
(10 µg/ml)  and (D) CoCr-PDOP-BMP Peptide (1000 µg/ml) substrates. 
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Surface texture by AFM 
 The surface roughness as determined by AFM (Fig. 6.6) was 139 ± 25 nm, 347 ± 
48nm, 363 ± 55 nm and 351 ± 49nm for pristine CoCr, CoCr-PDOP, CoCr-PDOP-BMP2 
(10 µg/ml) and CoCr-PDOP-BMP Peptide (1000 µg/ml) respectively. 
 
Figure 6.6 AFM images of (A) pristine CoCr, (B) CoCr-PDOP, (C) CoCr-PDOP BMP2 




  From the results (Fig.6.7) it is revealed that the number of osteoblasts on the 
CoCr-PDOP, CoCr-PDOP-BMP2(10 µg/ml) and CoCr-PDOP-BMP Peptide (1000 µg/ml) 
were significantly higher than that on the pristine CoCr. There is an approximately 
increase of about 30% for the CoCr-PDOP-BMP2 (10 µg/ml) and CoCr-PDOP-BMP 
Peptide (1000 µg/ml) compared to the pristine substrates. 
 
Figure 6.7 Number of adherent MC3T3-E1 per cm2 on surfaces of pristine CoCr, CoCr-
PDOP, CoCr-PDOP-BMP2 (10 µg/ml) and CoCr-PDOP-BMP Peptide (1000 µg/ml)  








 The cellular morphology of MC3T3-E1 on different substrates after 24 h 
cultivation was investigated using immunochemistry staining. Cell spreading on CoCr-
PDOP, CoCr-PDOP-BMP2 (10 µg/ml) and CoCr-PDOP-BMP Peptide (1000 µg/ml) 
were enhanced compared with that on pristine COCR (Fig. 6.8). Most of the cells on 
CoCr-PDOP, CoCr-PDOP-BMP2 (10 µg/ml) and CoCr-PDOP-BMP Peptide (1000 
µg/ml) substrates displayed a spindle shaped or elongated morphology whereas the cells 
on the pristine CoCr exhibited a stunted, less elongated morphology. 
 
Figure 6.8 Analysis of cell morphology of MC3T3-E1 on surfaces of (A) pristine CoCr, 
(B) CoCr-PDOP, (C) CoCr-PDOP-BMP2 (10 µg/ml) and (D) CoCr-PDOP-BMP Peptide 




ALP assay & calcium deposition 
 ALP activity was measured after the cells were cultured for 1 and 2 weeks on the 
substrates while calcium deposition was measured after the cells were cultured for 3 
weeks on the substrates. From Fig.6.9 & Fig.6.10, it can be seen that ALP activity and 
calcium deposition of the CoCr-PDOP-BMP2 (10 µg/ml) and CoCr-PDOP-BMP Peptide 
(1000 µg/ml) substrates were significantly higher than those on the pristine CoCr and 
CoCr-PDOP substrates, with a roughly 2 fold increase in ALP activity after 2 weeks 
incubation and a 4 fold increase in calcium content after 3 weeks incubation compared to 
the pristine substrate. 
 
 
Figure 6.9 ALP activity of MC3T3-E1 seeded on pristine CoCr, CoCr-PDOP, CoCr-
PDOP-BMP2 (10 µg/ml) and CoCr-PDOP-BMP Peptide (1000 µg/ml)  substrates on 




Figure 6.10 Calcium deposition of MC3T3-E1 seeded on pristine CoCr, CoCr-PDOP, 
CoCr-PDOP-BMP2 (10 µg/ml) and CoCr-PDOP-BMP Peptide (1000 µg/ml)  substrates 













Alizarin red staining 
 Approximately about one third of the cells were positively stained in the CoCr-
PDOP-BMP2 (10 µg/ml) and CoCr-PDOP-BMP Peptide (1000 µg/ml) substrates 
compared to the pristine CoCr and CoCr-PDOP substrates (Fig.6.11). 
 
Figure 6.11 Alizarin red staining for the presence of calcium deposits of MC3T3-E1 
seeded on (A) pristine CoCr, (B) CoCr-PDOP, (C) CoCr-PDOP-BMP2 (10 µg/ml) and 
(D) CoCr-PDOP-BMP Peptide (1000 µg/ml) substrates on week 3. The scale bar 








 Although the immobilization of BMP2 on CoCr substrates can enhance 
osteogenesis, however the cost is enormous. BMP2 is expensive and a single 
intervention can cost as much as US$5000, and this has become a major issue 
for clinicians, patients and payers alike [142]. BMP peptide, derived from the 
knuckle epitope of BMP2 is known to be involved in the processes of 
differentiation, calcification and binds to BMP2 receptors on osteoblastic cells 
stimulating ALP activity [42]. There have been several studies attempting to 
covalently immobilize peptides on various biomaterials [143-145]. Despite 
these studies demonstrating the effect of peptide-coated surfaces on in vitro 
cellular responses, there is still a lack of studies on the osteogenic effects of 
peptides specifically immobilized on CoCr surfaces. The immobilization of 
BMP Peptide on such devices would enhance bone healing and regeneration 
by stimulating and recruiting host osteoblasts or osteoprogenitor cells.  
 Therefore in this study, we determined the effects of CoCr covalently grafted with 
BMP Peptide on osteoblastic cells. First we had to determine the equivalent functional 
dosages of BMP Peptide to BMP2 to elicit close or similar osteogenic responses. BMP 
Peptide and BMP2 is known to stimulate osteoblastic differentiation and proliferation 
[133, 146], therefore a comparison of MC3T3-E1 proliferation between BMP Peptide and 
BMP2 at various dosages of functionalization was performed. From Fig. 6.1 it was found 
that covalent immobilization of BMP Peptide at 1000 µg/ml would be close to BMP2 at 
10 µg/ml for similar biological responses. Subsequently all further tests were performed 
at these 2 concentrations for comparison. Although the amount of synthetic peptide used 
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for the bioconjugation of BMP Peptide (1000 µg/ml) is higher than that compared to 
BMP2 (10 µg/ml), its use is till a viable option and translates to a substantial amount of 
savings in clinical applications. 
 To determine the distribution of the immobilized peptide, OPA assay was 
conducted to assess the surface distribution of the BMP Peptide on the polydopamine 
coated substrates. A very strong fluorescence was observed on the peptide-coated 
substrates due to reaction of OPA with the peptide moiety. These results (Fig. 6.2) 
showed the random dispersion of the immobilized peptide and demonstrated the ability to 
graft these amino acid groups to the biomimetic layer. The addition of the cys-tag for site 
specific conjugation with thiol directed chemistry conferred high binding efficiency of 
the peptide with the biomimetic layer, with over 90% for all the various concentrations 
used as shown in table 6.1.  
 MTT assay performed on the various substrates on day 7 of culture showed 
significantly higher viability of MC3T3-E1 on the CoCr-PDOP-BMP2 (10 µg/ml)  and 
CoCr-PDOP-BMP Peptide (1000 µg/ml) substrates compared to both the pristine CoCr 
and CoCr-PDOP (Fig.6.3) substrates. The results suggest that CoCr-PDOP-BMP2 (10 
µg/ml)  and CoCr-PDOP-BMP Peptide (1000 µg/ml) substrates were not cytotoxic to the 
cells, and the immobilized bioactive factors on the surfaces can promote the survival of 
MC3T3-E1. 
 BMP signaling depends on Smad1, 5 and 8 which are activated in response to 
BMP treatment. Immunostaining performed revealed that the peptide-coated substrates 
were able to stimulate the osteoblastic cells as reflected by the upregulated 
phosphorylation of Smad1/5/8 (Fig. 6.4). Surface roughness affect osteogenesis [147] and 
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generally rough implant surfaces are known to be superior with regards to cellular 
attachment and osteogenesis [148]. The AFM results (Fig. 6.6) showed an increase in 
surface roughness after the covalent immobilization. Results of this study showed that the 
peptide-coated CoCr substrates significantly enhanced osteoblastic cell adhesion 
compared to unmodified CoCr substrates. With peptide attachment the surface roughness 
was close to that for CoCr-PDOP, but the changes in cellular attachment was markedly 
increased (Fig. 6.7), and the main factor is likely to be due to the added peptide. The 
biological activity of the immobilized peptide plays a critical role during implant 
integration as cells come into direct contact with the implant surface. The nature of this 
initial attachment and adhesion influences the cell’s capacity to proliferate and 
differentiate [148] and ultimately the success or failure of the implant.  
 Morphological studies (Fig. 6.8) showed that the cells seeded on the pristine CoCr 
appear stunted and less elongated while cells seeded on CoCr-PDOP-BMP2 (10 µg/ml)  
and CoCr-PDOP-BMP Peptide (1000 µg/ml) substrates exhibited more spreading and 
increased bundles of actin microfilaments compared to both the pristine CoCr and CoCr-
PDOP substrates. This is indicative of a generally healthier morphology and increased 
faster differentiation rate [133]. This was corroborated by the ALP activity and calcium 
deposition results, where we observed a 2-fold increase in ALP activity after 2 weeks and 
a 4-fold increase in calcium content after 3 weeks (Fig. 6.9, 6.10). It can be seen that ALP 
activity of the osteoblastic cells on the CoCr-PDOP substrates is at a similar level as the 
ALP activity on the pristine CoCr substrates throughout the 2 weeks period. On the other 
hand, osteoblastic cells cultivated on the peptide-coated substrates have a significantly 
higher ALP activity. Similar to the ALP results there is no significant difference in 
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calcium deposition between the pristine CoCr and CoCr-PDOP substrates while the 
calcium deposition on the peptide-coated substrates were increased significantly. Alizarin 
Red was used to visualize the extent of mineralization. In the presence of the BMP 
Peptide, mineralization is greatly enhanced as indicated by the dense coverage of the 
calcium deposits on the peptide-coated substrates (Fig. 6.10).  
 To ensure that the increased osteogenic effects observed were not confounded by 
the release of the immobilized BMP2 or BMP peptide into the culture medium, MC3T3-
E1 cells were cultured on a permeable support (0.4 μm pore size, Costar®, Corning) in 
transwells with or without substrates immobilized with BMP2 or BMP Peptide for 3 
weeks (results not shown). No significant differences were observed in cell viability, 
ALP and calcium deposition tests between the groups. This indicated that the enhanced 
osteogenesis observed was due to the immobilized factors and not the soluble forms 










6.5  Conclusion 
 In summary, we have shown that immobilization of BMP Peptide onto the surface 
of metal substrates may be a viable option in promoting osteogenesis and enhanced 
implant integration. By immobilizing BMP Peptide onto a metal substrate using a 
cysteine placement for site-specific conjugation with the biomimetic polymer film, we 
have demonstrated that the modified substrate promotes the differentiation and 
mineralization of osteoblastic cells. This enhanced osteogenesis is beneficial in 
accelerating wound healing and new bone tissue formation. Although results achieved 
with the BMP Peptide are slightly lower to those seen with BMP2, but that is at one tenth 
of the cost. The usage of BMP Peptide in implant functionalization is hence, a cheaper 
















Conclusion of  study 
 
 There is an ever growing need for orthopaedic advancement with the high 
prevalence and impact of musculoskeletal diseases. 50% of the world's population over 
65 suffer from joint diseases and more than 25% of population over 65 require health 
care for joint related diseases. The instances for failed joint replacements associated with 
osteolysis and bone defects is increasing. There is an urgency to increase the success of 
bone implant fixation and the longevity of implant. Fixation of orthopaedic implants has 
been one of the most challenging and difficult problem faced by orthopaedic surgeons 
and patients. Fixation can often be achieved via direct biological fixation by allowing 
tissues to grow into the surfaces of the implants or with the use of bone cement acting as 
a grouting material. Whether cemented or cementless fixation are employed, the 
problems of micromotion and the generation of wear particles may eventually necessitate 
further surgery.  Revision surgery poses increased risks like deep venous thrombosis, 
infection and dislocation, in addition to being an economic burden to the patient. 
Therefore the enhancement of implant integration would bring enormous benefits.  
 The basis of clinical strategies to manage bone defects would center around the 
fundamentals of orthobiological therapies based on osteoconduction (structure) and 
osteoinduction (growth factors). Therefore to increase the rate of implant integration and 
to reduce revision surgery, our study investigated these factors for improving bone 
regeneration. 1) Metallic alloys (Ti and CoCr) which provided the structural matrix for 
mechanical function, delivery of growth factors, cellular support and cell fixation. 2) 
Bioactive factors (VEGF, BMP2 and BMP peptide) that induce bone formation, increases 
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cellular proliferation and for facilitating early angiogenesis.  These two factors have 
major impact in osteogenic enhancement of bone defects especially those with limited 
healing potential.  
 One of the main problems encountered with biomaterials for surface 
functionalizaton is the lack of reactivity and suitable binding groups on the surface. For 
more functions and flexibility, the concentrations of reactive groups such as amino, 
carboxyl and phenolic group of tyrosine have to be increased. This initial organic layer 
deposited on the biomaterials can then by used as a tether for bioactive factors which can 
be used for enhancement of the bone-implant interface. Another issue is the control of the 
retention and/or release of the bioactive factors from the implant surface. The easiest 
method often employed is physical adsorption, which provides little control over the 
delivery of the bioactive factors. Considering the risks of using soluble or non-covalently 
immobilized growth factors for therapeutic interventions, the use of covalently 
immobilized growth factors would provide significant advantages. Deleterious effects 
such as unwanted ectopic bone formation, high levels of growth factors in the local 
microenvironment and the risk of undesirable effects at locations beyond the implant site 
can be avoided.  
 Despite the good inherent bioactivity and biocompatibility exhibited by Titanium 
alloys, osseointegration with host tissue is still not definite, the lack of vascularity may 
cause implant failure at times. Cobalt Chromium alloys are one of the strongest metal in 
use today for orthopaedic implants, unfortunately osseointegrative properties are almost 
non-existence for Cobalt Chromium implants. Strategies were developed in this thesis to 
overcome the challenges of insufficient vascularity and osteogenesis faced by these 
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implant materials. Although it is not possible to have a universal means of surface 
functionalization, however our study has developed a viable technique which may be 
applied to applications where enhancing the host implant interface would be of crucial 
importance. 
 With the ever growing number of patients requiring orthopaedic reconstructions, a 
rapid translation of basic research for use in clinical disease diagnosis, prevention and 
treatment is crucial, employing medical research towards a patient-oriented approach. 
Structural reconstruction based implants have limitations associated with bone fixation 
and osteolysis. Therefore the development and evolvement of implant material with 
structural and biological potential to manage bone healing impairment and defects would 
be desirable. The control of surface function with immobilization holds great potential for 
creating biofunctional implant materials to provide for enhanced osseointegration. The 
studies performed in this thesis showed for the first time the effectiveness of using 
covalent bioconjugation of bioactive factors with polydopamine onto metallic substrates 
which can potentially be used for the development of orthopaedic devices for enhancing 
the chances of successful implant integration. This would assist patients in maintaining a 
good quality of life and remain independent longer with advancing years. Recent in vivo 
evaluation of polydopamine [149] has shown it to be non toxic which would further 








Recommendations for future study 
 The work in this thesis has shown that it is possible to confer bioactivity to 
implant materials for enhancing osseointegration. Possible future work can look at the 
use of multiple biochemical cues to simulate revascularization which remains an 
inadequately resolved challenge. The presence of VEGF may not be sufficient and other 
promaturing factors such as angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) may be 
required for vascular integrity and development. Work can also be done to examine the 
angiogenic effects and the osteogenic effects of these functionalized substrates in vivo. A 
detailed study of the functionalized substrates in an in vivo setting will yield useful 
information such as response of bone to the implant, the rate of implant fixation and bone 
ingrowth which will be crucial for further improving the modification process of the 
substrates. An investigation into the immunological response after implantation can also 
be evaluated. The process of bone healing is intricately linked with immune responses 
therefore a study of the osteoimmunology of bone healing in vivo will provide vital 
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